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1 Introduction 
 Definition of COPD 
Chronic obstructive pulmonary disease (COPD) is a major global health problem, since an estimated 
64 million people suffered from COPD in 2004 (Mathers et al., 2008). In 2005 more than 3 million 
people died of COPD, which is equal to 5% of all global deaths this year. The World Health 
Organization (WHO) ranked COPD as the third common cause of death worldwide and estimates that 
it will be the third by 2020 (WHO, 2008). Furthermore, COPD is one of the leading causes for 
hospitalization and health care incurrence (Buist et al., 2007; Gershon et al., 2010; Hall et al., 2010). 
COPD is a highly under-diagnosed disease and often diagnosed in a late stage. Cigarette smoking is 
the major cause for COPD in the industrialized countries where it accounts for 80 – 90 % of the cases 
(Barnes et al., 2003) . Earlier diagnosis would be important for aggressive smoking cessation efforts 
and by this may lead to a reduction in the burden of COPD symptoms (Tinkelman et al., 2007).  In 
developing countries other environmental pollutants such as indoor air pollution from combustion of 
biomass/traditional fuels and coal are important causes of COPD (Dennis et al., 1996). Next to CS 
and air pollution, genetic predispositions are risk factors for developing COPD. The lack of proteinase 
inhibitor α-1-antitrypsin in the lung and a polymorphism of the promoter region of the pro-inflammatory 
cytokine tumor necrosis factor-α (TNF-α) have been associated with COPD development (WHO, 
1997). Inflammatory changes are detectable in lungs of all smokers, independently of disease 
development, but in COPD inflammatory processes seem to be abnormal (Chung and Adcock, 2008). 
Deregulated inflammatory responses can subsequently cause mucus hypersecretion (chronic 
bronchitis) (Sommerhoff et al., 1990) ), tissue destruction (emphysema) (Lee et al., 2007; Sullivan et 
al., 2005; Turato et al., 2002) as well as disruption of repair- and defense mechanisms (Rennard, 
2007). Together these pathological changes lead to increased resistance to airflow in the small 
conducting airways, and increased compliance and reduced elastic recoil in the lungs. Consequences 
are progressive airflow limitations and air trapping, which are the hallmarks of COPD. In general, 
inflammatory and structural changes persist even after smoking cessation and increase with disease 
severity. 
 COPD classification 
Since all COPD patients exhibit airflow limitation with reduced expiratory flow rates, the GOLD 
committee defines COPD on the basis of spirometric criteria. The severity of air flow limitation is 
determined by measuring the forced expiratory volume in one second (FEV1) and its ratio to the 
forced vital capacity (FVC) that can be expired without time limit. Both parameters are reliable 
screening tools because both are affected by airway obstruction and by emphysema. The GOLD 
committee designates that an FEV1/FVC ratio of less than 70% indicates COPD. Depending on 
FEV1/FVC ratios in combination with FEV1 alone the GOLD committee defines 4 severity stages of 
COPD (Table 1). Cessation of cigarette smoking has a beneficial effect at any age, but can only delay 
and not stop COPD progression (Hogg, 2008; Pauwels et al., 2001; Rabe et al., 2007) . 
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Table 1: Spirometric classification of COPD severity based on post-bronchodilator FEV1 
COPD GOLD stage Spirometric data 
Stage I: Mild FEV1/FVC < 0.70 
FEV1 ≥ 80% predicted 
Stage II: Moderate FEV1/FVC < 0.70 
50% ≤ FEV1 < 80% predicted 
Stage III: Severe FEV1/FVC < 0.70 
30% ≤ FEV1 < 50% predicted 
Stage IV: Very Severe 
 
FEV1/FVC < 0.70 
FEV1 < 30% predicted or FEV1 < 50% predicted 
plus chronic respiratory failure* 
*respiratory failure: arterial partial pressure of oxygen (PaO2) less than 8.0 kPa (60 mm Hg) with or without arterial partial pressure of 
CO2 (PaCO2) greater than 6.7 kPa(50 mm Hg) while breathing air at sea level.  
(adapted from: The Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease, Global 
Initiative for Chronic Obstructive Lung Disease (GOLD) (2006)) 
 
In 2011 the GOLD committee approved that the extent of symptoms, health status impairment and 
risk of exacerbations can poorly be predicted by the FEV1 alone. As a first step towards personalized 
therapy a reorganization of treatment objectives into two categories (relief of present symptoms and 
reduction in the risk of future adverse health effects) was conducted. The new system (Table 2) aimed 
at increasing the match between clinical assessment and specific treatment options. Therefore, 
amongst others the COPD assessment test (CAT), which is a questionnaire assessing the impact of 
COPD (cough, sputum, chest tightness, dyspnea) on health status and the modified Medical 
Research Council (mMRC) dyspnoea scale were implemented. 
Table 2: New GOLD classification and therapy 
Patient 
Group 
A 
(low risk, less 
symptoms) 
B 
(low risk, more 
symptoms) 
C 
(high risk, less 
symptoms) 
D 
(high risk, more 
symptoms) 
 
B
u
rd
e
n
 o
f 
S
y
m
p
to
m
s
 GOLD I - GOLD II (FEV>50% predicted) 
and/or 0-1 exacerbation p.a. and no 
hospitalization for exacerbation; and 
GOLD III - GOLD IV (FEV<50% predicted) 
and/or ≥ 2 exacerbations p.a. or ≥ 1 with 
hospitalization for exacerbation; and 
CAT score < 10 or 
mMRC grade 0-1 
CAT score ≥ 10 or 
mMRC grade ≥ 2 
CAT score 10 or 
mMRC grade 0-1 
CAT score ≥ 10 or 
mMRC grade ≥ 2 
T
re
a
tm
e
n
t 
active reduction of risk factor(s) e.g. influenza vaccination; short-acting bronchodilator (when 
needed) 
 
regular treatment with one or more long-acting bronchodilators (when 
needed); rehabilitation 
 
 inhaled glucocorticosteroids if repeated 
exacerbations 
 
  long term oxygen if 
chronic respiratory 
failure; 
consideration of 
surgical treatments 
(Adapted from: The Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease, Global 
Initiative for Chronic Obstructive Lung Disease (GOLD) 2009 & 2015) 
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 Pathophysiology of COPD 
The three main hallmarks of COPD pathophysiology are airway obstruction, chronic bronchitis and 
emphysema, as defined by the Global Initiative for Chronic Obstructive Lung Disease Guidelines 
(GOLD) (Pauwels et al., 2001).  Airway obstruction, which in COPD is mainly irreversible, results from 
a combination of small airway narrowing (small airway obstruction), increased inflammation of the 
airways and mucus production (chronic bronchitis) (Cosio et al. 1978) and destruction of lung 
parenchyma (emphysema) accompanied by loss of lung elastic recoil (Colebatch et al., 1973; Penman 
et al., 1970). Chronic bronchitis is described as inflammation located in the epithelium of the central 
airways, which also affects mucus-producing glands (Mullen et al., 1985; Saetta et al., 1997). These 
inflammatory processes subsequently lead to mucus hypersecretion, defects in the mucociliary 
clearance, and disruption of the epithelial barrier. Cells of the innate and the adaptive immune system 
are involved in these processes (Lacoste et al., 1993; Saetta et al., 1993, 1997). The thickening of 
bronchial walls which is associated with chronic bronchitis is mainly due to increased connective 
tissue deposition and there is evidence that growth factors such as transforming growth factor-β (TGF-
β) are responsible for this circumstance (Vignola et al. 1997; Hogg 2004). Although the terms chronic 
bronchitis and airway obstruction are often used in the same context, obstruction is preferentially 
found in the smaller conducting airways (Hogg et al. 1968; Van Brabandt et al. 1983; Yanai et al. 
1992). Although the accumulation of inflammatory exudates in the small-airway lumen might be 
related to an extension of chronic bronchitis into the small airways, results of several studies give 
evidence that this is not the case. It was shown by two clinical trials that the development of airflow 
limitation is not predicted by the presence of chronic bronchitis (Fletcher et al., 1976; Vestbo and 
Lange, 2002). In addition, pathological studies indicate that inflammation of central and peripheral 
airways can occur independently of each other (Mullen et al., 1985). These data lead to the conclusion 
that chronic bronchitis is independent of disease processes occurring in the small airways, which are 
responsible for airway obstruction in COPD patients (Hogg et al., 2004).  Beside small airway disease 
and chronic bronchitis, COPD is characterized by emphysema. Emphysema is defined as “abnormal 
permanent enlargement of air spaces distal to terminal bronchioles, accompanied by destruction of 
their walls without obvious fibrosis.” (ATS, 1962; Snider et al., 1985). Emphysematous changes lead 
to reduction of elastic recoil, which is the force responsible for driving expiratory flow (Mead et al., 
1967). Furthermore,  emphysema worsens diffusion capacity by reducing gas exchange area 
(Pauwels et al., 2001; Rodriguez-Roisin et al., 2009). 
 COPD symptoms include: shortness of breath (dyspnea), wheezing, chest tightness, chronic cough 
that induces sputum, blueness of the lips or fingernail beds (cyanosis), frequent respiratory infections, 
lack of energy and, at later stages, loss of weight. 
 Immunopathogenesis of COPD 
Inhalation of toxic particles firstly leads to activation of the innate immune system, which provides the 
first line of defense and is important to maintain sterility in the lower respiratory tract (Hogg, 2008). 
Components of the innate immune system of the lung include the mucuciliary clearance apparatus, 
the epithelial barrier and the innate immune cells (Green et al., 1977; Knowles and Boucher, 2002). 
Chronic CS exposure leads to reduced mucociliary clearance, increased mucus production (Cohen 
et al., 1979; Vastag et al., 1984) and disruption of the tight junctions (Hulbert et al., 1981; Jones et 
al., 1980; Simani et al., 1974) that form the epithelial cell barrier. Consequently, this results in an 
invasion of polymorphonuclear cells, mononuclear phagocytes, and natural killer cells into the 
damaged tissue (Kumar et al., 2005). Dendritic cells bridge innate and adaptive immune response by 
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presenting antigen to lymphocytes located in T and B cell zones within lymphoid follicles (Hogg, 2008; 
Hogg et al., 2004). 
CS and other air pollutants lead to an activation of neutrophils and epithelial cells in the respiratory 
tract via the activation of toll like receptors (TLRs) and the induction of oxidative stress (Brusselle et 
al., 2011). Subsequently, neutrophils and epithelial cells release multiple chemoattractants, mainly 
chemokines to attract more neutrophils and monocytes as well as T lymphocytes (Becker et al., 2002; 
Fujii et al., 2001, 2002; Gilmour et al., 2001). All types of activated cells secrete inflammatory 
mediators and additionally, several cell types, including neutrophils and epithelial cells release 
proteases such as neutrophil elastase (NE) and matrix metalloproteinases (MMPs) (Caughey, 1994; 
Lieberman, 2003; Shapiro, 2012; Taggart et al., 2005). An increase of proteases leads to a protease-
antiprotease imbalance and hence, on the one hand to destruction of connective tissue in the lung 
parenchyma, resulting in emphysema (Churg and Wright, 2005; MacNee, 2005) and on the other 
hand to stimulation of mucus hypersecretion (chronic bronchitis) (Nadel, 2000; Sommerhoff et al., 
1990; Takeyama et al., 1998). TGF-β release by macrophages and epithelial cells stimulates 
fibroblast proliferation, leading to fibrosis in the small airways (Epstein et al., 1994; Wynn, 2011). 
Moreover, the adaptive part of the immune system has been shown to be involved in COPD 
pathogenesis. For instance, an association between increased numbers of CD8+ T cells and the 
severity stage of COPD has been observed (O’Shaughnessy and Ansari, 1997; Saetta et al., 1999). 
Usually, activated CD8+ T cells have a protective function by releasing proteolytic enzymes which 
induce cell death of virus-infected cells, but in the case of COPD they are described to be involved in 
the destruction of lung parenchyma (Cosio et al., 2002; Majo et al., 2001). Furthermore, CD4+ T cells 
show increased numbers in the airways and lungs of smokers with COPD (Finkelstein et al., 1995). 
At least two types of effector CD4 T helper (Th) cell subsets accumulate in the lungs of patients with 
stable COPD: Th1 and Th17 cells (Grumelli et al., 2004; Di Stefano et al., 2009). Th1 cells release 
interferon-γ (IFN-γ) and promote the recruitment of inflammatory cells into the lung (Grumelli et al., 
2004). IL-18, which promotes Th1 cell development, is highly expressed in alveolar macrophages, 
CD8+ T cells, and alveolar and bronchiolar epithelial cells in the lungs of patients that suffer from 
severe COPD (Imaoka et al., 2008). Th17 cells, which are characterized by the secretion of IL-17A, 
IL-17F, IL-22 and IL-23, play a central role in the defense against extracellular pathogens but are also 
involved in autoimmunity (Miossec et al., 2009). Th17 cells promote the accumulation of neutrophils 
at the site of tissue injury by inducing epithelial cells to produce antimicrobial peptides (such as β-
defensins) (Kao et al., 2004), chemokines and the granulocyte growth factors GM-CSF and G-CSF 
(Traves and Donnelly, 2008). Di Stefano et al. demonstrated that COPD patients have increased 
numbers of IL-23+ cells in bronchial epithelium and IL-17+ cells in bronchial submucosa (Di Stefano 
et al., 2009). A distinct T helper effector cell lineage are regulatory T cells (Treg), which regulate 
inflammatory processes and inhibit autoimmunity. Tregs exert their suppressive functions on other T 
cells or antigen presenting dendritic cells via cell-cell contacts or the secrection of anti-inflammatory 
cytokines such as IL-10 and TGF-β (Tang and Bluestone, 2008). Tregs are characterized by the 
expression of the surface marker CD25 and the transcription factor Foxp3. Decreased numbers of 
regulatory T cells, lower Foxp3 mRNA expression levels and less secretion of IL-10 have been shown 
in the whole lung of COPD specimens compared to controls (Brusselle et al., 2011; Lee et al., 2007). 
In summary, COPD appears to represent an amplification of the normal response of the respiratory 
mucosa to inhaled irritants associated with limited regulatory control.  
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 The key immune cells involved in COPD 
 B cells and inducible bronchus-associated lymphoid tissue in COPD  
Aside from T cells also B cell numbers have been shown to be increased in the large airways of COPD 
patients (Gosman et al., 2006). The presence of B cells points to an antigen-driven specific immune 
response that contributes to the inflammatory process and the development and perpetuation of 
COPD (Brandsma et al., 2009; Lee et al., 2007). Increasing evidence suggests that antigens triggering 
this specific immune response in COPD patients might not only include tobacco smoke residues but 
also extracellular matrix components resulting from smoke-induced lung tissue destruction 
(Brandsma et al., 2009; Feghali-Bostwick and Gadgil, 2008). Lee et al. provided the most conclusive 
results supporting a role of autoimmune components in COPD and described immune responses 
against lung elastin as shown by the presence of anti-elastin antibodies and specific Th1 responses 
in patients with emphysema (Lee et al., 2007). However, these results could not be confirmed by 
more recent studies performed by Cottin et al. and Greene et al. (Brandsma et al., 2011; Cottin et al., 
2009; Greene et al., 2010). Furthermore, autoimmune responses against airway epithelial cells, 
endothelial cells, several immunogenic peptides, and cytokeratin have also been described for COPD 
(Brandsma et al., 2011). These findings and the fact that immune cells persist even after smoking 
cessation (Hogg et al., 2004; Rutgers et al., 2000; Wright et al., 1983) nevertheless support the 
hypothesis that COPD might have an autoimmune component characterized by inflammatory 
responses against auto- and neo-antigens. Moreover, especially in patients with severe and very 
severe COPD, B cells are found in organized structures called tertiary lymphoid follicles organs (TLO) 
(Hogg et al., 2004). Lymphoid follicles are special anatomical structures which are well organized and 
consist of memory and naïve B cells, T lymphocytes, dendritic cells and follicular dendritic cells 
(FDCs) which allow priming, clonal expansion of B cells and T cells, antigen retention, somatic 
hypermutation, affinity maturation and immunoglobulin (Ig) class switching (Aloisi and Pujol-Borrell, 
2006; Kroese et al., 1990; MacLennan, 1994). Lymphoid neogenesis is a dynamic process starting 
with slight lymphocyte infiltrates which result in aggregates or even organized B cell follicles with 
germinal centers and distinct T cell areas containing DCs and high endothelial venules (HEVs) (Aloisi 
and Pujol-Borrell, 2006; Armengol et al., 2001; Hjelmström, 2001; et al., 2005; Salomonsson et al., 
2003). Via HEVs extravasation of B and T cells is regulated. In COPD, TLOs in the lung contain 
aggregates of B cells surrounded by T cells. The T cells are mainly CD4+ (80-90%) and only 10-20% 
CD8+ (Hogg, 2004; Hogg et al., 2004; van der Strate et al., 2006). B cells found in these follicles are 
mainly IgM positive and IgD negative, a fact leading to the assumption that these B cells are activated 
to some extent. Furthermore, many cells in these infiltrates express the surface marker CD27, a 
marker for memory B cells (Zubler, 2001). As already found in other tissues affected by chronic 
inflammation, TLOs in COPD arise from lymphoid neogenesis and therefore belong to the inducible 
bronchus-associated lymphoid tissue (iBALT). iBALT is defined as ectopic lymphoid tissue, which is 
formed in response to chronic infection or inflammation and collects antigens from the airways. It 
induces local inflammatory responses and is responsible for the maintenance of memory cells in the 
lungs (Brusselle et al., 2009; Randall, 2010). In COPD patients the presence and size of iBALT 
structures in the lung correlate with disease severity (Hogg et al., 2004). Similar observations were 
made for mice exposed to tobacco smoke (van der Strate et al., 2006). Thus, iBALT is likely to be 
involved in COPD pathogenesis, however its definite role is still unknown. In general, iBALT might 
protect from microbial colonization and infection of the lower respiratory tract. Two recent studies 
addressed the question of lymphoid neogenesis in the COPD lung and emphasized an important role 
for CXCL13. Litsiou et al. discovered an involvement of CXCL13 in lymphoid neogenesis in COPD 
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patients by promoting B cell migration to ectopic sites of lymphoid tissue formation. Additionally, 
upregulation of lymphotoxin on B cells, which in turn further induces CXCL13 in a positive feedback 
loop, was reported (Litsiou et al., 2013). Chronic CS exposure of mice leads to increased CXCL13 
levels in BAL and lung tissue and subsequently to B cell chemotaxis as well (Bracke et al., 2013). 
Furthermore, Bracke et al. observed increased CXCL13 levels in lung tissue and induced sputum of 
COPD patients. By prophylactic and therapeutic administration of a CXCL13 neutralizing antibody in 
a COPD mouse model they could inhibit iBALT formation. In the absence of iBALT these mice showed 
less BAL inflammation and were partially protected against destruction of alveolar walls (Bracke et 
al., 2013). In line with these findings, recently published results by Morisette et al. showed the 
persistence of iBALT even after smoking cessation. The authors observed a strong association of 
iBALT structures with antinuclear antibodies (ANAs) (Morissette et al., 2014). Interestingly, CCR7 
deficient mice spontaneously develop iBALT. The authors reason that this phenomenon is caused by 
absent homing of Tregs via the homing receptor CCR7 to the lung-draining bronchial lymph nodes. 
Adoptive transfer of Wt Treg cells to CCR7-/- recipients attenuated iBALT (Kocks et al., 2007). Thus, 
Treg cells seem to be involved in controlling iBALT formation. Demoor et al. conducted a study 
exposing CCR7-/- mice chronically to CS, and emphysematous changes in CCR7-/- mice caused by 
CS-exposure were not significant compared to CCR7-/- mice under filter air conditions. However, 
compared to Wt mice, CCR7-/- mice showed a significant airspace enlargement on baseline level 
(Demoor et al., 2009). Altogether, these findings strongly point to an important role of iBALT structures 
in COPD pathogenesis.  
Aside from their involvement in lymphoid neogenesis and their antibody-producing capacity, B cells 
can also function as antigen-presenting cells and provide costimulatory signals to T cells (DiLillo et 
al., 2011). Furthermore, the secretion of a variety of cytokines enables B cells to influence the 
differentiation and polarization of T cells, macrophages and dendritic cells during immune reactions. 
For instance IL-10 producing B cells with an immune modulatory role are described for EAE 
(experimental autoimmune encephalomyelitis), the murine model for multiple sclerosis (MS) 
(Fillatreau et al., 2002). B cells directly stimulate IFN-γ secretion and proliferation of Th1 cells (Harris 
et al., 2005). Since B cells secrete TGF-β as well as IL-6 (Pistoia, 1997), which are described to be 
critical for Th17 differentiation, they might also be involved in bolstering Th17 responses. Depletion 
of B cells in RA (rheumatoid arthritis) patients decreases Th17 responses, as measured by the 
number of Th17 cells in synovial tissue as well as expression of Rorγt and IL-22 (van de Veerdonk et 
al., 2011). B cells are also capable of modulating macrophage effector functions via cytokine 
secretion, which has been described to be important for the outcome of various models of infection, 
inflammation and cancer (Biswas and Mantovani, 2010; Moseman et al., 2012; Wong et al., 2010). B 
cell derived IL-10 negatively regulates the expression of pro-inflammatory genes such as TNF-α, 
CCL3 and IL-1-β, and up-regulates IL-10 expression in LPS stimulated macrophages (Wong et al., 
2010). Furthermore, Popi et al. observed that innate-like B1 B cells down-regulate macrophage 
activities, including phagocytic capacity and the release of nitric oxide as well as hydrogen peroxide. 
Using transwell experiments with macrophages and B1 cells from either IL-10 knockout mice or Wt 
mice Popi et al. demonstrated that only Wt B1 cells were able to influence the phagocytic potential of 
Wt macrophages (Popi et al., 2004). These observations indicate that B1 cells via IL-10 have the 
ability to influence macrophages via the secretion of soluble mediators. In a transgenic mouse model 
of multistage epithelial carcinogenesis using K14-HPV16 mice, B cells were shown to foster pro-
tumoral properties of macrophages via activation of Fcγ receptors on macrophage surfaces. IgGs 
secreted by B cells interact with Fcγ receptors on resident and recruited macrophages and promote 
M2 polarization since macrophages isolated from HPV16/FcRγ+/- versus HPV16/FcRγ-/- skin revealed 
a significant upregulation of M2 characterizing genes (IL-13, CD163, CCL17, IL-4, and Ym1) (Andreu 
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et al., 2010). Results from Wong et al. support the hypothesis of B cell mediated M2 polarization via 
IL-10 secretion. Wong and colleagues have shown that B1-induced M2 polarization was prevented 
by inhibition of IL-10 (Wong et al., 2010) .  
 Macrophages in COPD 
Macrophages play a central role in the inflammatory processes in COPD and account for most of the 
features of the disease pathogenesis. Former studies involving the depletion of either neutrophils or 
macrophages have shown that only mice deprived of macrophages are protected against emphysema 
development. Similarly, the absence of MMP12, mainly produced by macrophages, protects mice 
against loss of alveolar structures even though they still can produce neutrophil elastase (Brusselle, 
2009; Hautamaki et al., 1997). The role of different macrophage phenotypes in COPD is the topic of 
several recently conducted studies.  
M1 or classically activated macrophages are activated when exposed to IFN-γ or TNF-α and are 
under the influence of the transcription factor IRF5. They are characterized by generating reactive 
oxygen species (ROS) and nitric oxide (NO) and by amplifying Th1 responses by secreting pro-
inflammatory cytokines such as IL-12, IL-1β and TNFα thereby contributing to host defense against 
intracellular pathogens (Biswas and Mantovani, 2010; Krausgruber et al., 2011). In contrast, M2 
macrophages are induced by IL-4 and IL-13 (Gordon, 2003; Stein et al., 1992) under the influence of 
the transcription factor IRF4 (Satoh et al., 2010). They are associated with protection against 
helminthes and with physiological and pathological tissue remodeling (Boorsma et al., 2013; Martinez 
et al., 2009; Mosser and Edwards, 2008). Thus, M2 macrophages are also considered as wound-
healing macrophages.  
Relating to an involvement of different macrophage phenotypes in COPD pathogenesis, conflicting 
data exist. Several studies point to a role for M1 macrophages or dysregulated M1 macrophages in 
the development of COPD. CS, the most important risk factor for COPD, contains lipopolysaccharide 
(LPS) which activates macrophages in the lung resulting in increased iNOS espression (Stedman, 
1968). Upregulated iNOS expression in turn is an indicator for M1 activation. iNOS subsequently 
leads to increases in ROS and NO causing further oxidative stress adding to the oxidative stress 
originating from CS per se and contributing to COPD (Ito, 2009; Montuschi et al., 2000; Paredi et al.; 
Rahman et al., 2002). Additionally smoking induces pro-inflammatory M1 derived cytokines such as 
TNF-α, IL-6, IL-8 and IL-1β (Demirjian et al., 2006; Doz et al., 2008; Facchinetti et al., 2007; Karimi et 
al., 2006; Walters et al., 2005; Yang et al., 2006), which were also found to be up-regulated in COPD 
(Bucchioni et al., 2003; Sapey et al., 2009; Yamamoto and Yoneda, 1997). In experimental settings 
over-expression of TNF-α in mouse lung tissue was shown to induce development of chronic 
inflammation and emphysema (Fujita et al., 2001; Thomson et al., 2012; Vuillemenot et al., 2004). 
However, therapeutic application of anti-TNF-α antibodies in humans seems to be ineffective in COPD 
treatment (Matera et al., 2010). Another M1 cytokine, IL-1-β, was found to cause lung inflammation, 
emphysema, mucus metaplasia, and airway fibrosis when over-expressed in mouse lungs 
(Lappalainen et al., 2005). Furthermore, over-expressing IFN-γ, a M1 related cytokine produced by 
CD8+ cells infiltrating lungs in COPD and inducing the M1 phenotype, led to an imbalance of MMPs 
and antiproteases in mice (Wang et al., 2012). On the other hand, IFNγR and IFN-γ signaling were 
found to be down-regulated in COPD patients. Another important property of M1 macrophages is 
phagocytosis, which has been shown to be impaired in COPD and thus contributes to persistence of 
microorganisms in the exacerbated lung of COPD patients (Berenson et al., 2006; PRIETO et al., 
2001; Taylor et al., 2010). In their review article, Boorsma et al. reason that rather a dysregulated M1 
macrophage phenotype than an increased or decreased number of M1 macrophages plays a role in 
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COPD. The authors justify their conclusion with dissonant results for M1 marker molecules or 
functions, with some being up-regulated under COPD conditions (ROS generation, pro-inflammatory 
cytokines) and some down-regulated (phagocytosis, IFN-γ responsiveness) (Boorsma et al., 2013). 
Over-expression of IFN-γ, which induces the M1 phenotype, results in emphysema development just 
as well as over-expression of the M2 inducer IL-13 (Boorsma et al., 2013). IL-13 producing M2 
macrophages were observed in lung tissue of COPD patients, giving a hint that also M2 macrophages 
are involved in COPD pathogenesis (Kim et al., 2008). Shaykhiev et al. analyzed and compared the 
transcriptome of alveolar macrophages from healthy smokers, nonsmokers and COPD smokers and 
demonstrated a smoking-induced reprogramming of alveolar macrophages toward an M1-
deactivated, partially M2 polarized phenotype. In mice M2 macrophages characteristically express 
large amounts of the chitinase-like proteins Ym1 and Ym2 (Chi3l3/4) (Shaykhiev et al., 2009). Using 
mouse models of chronic obstructive lung diseases, Agapov et al. observed an up-regulation of Ym1 
and Ym2 correlating with disease progression. Since Ym1 and Ym2 have no human homologs, 
Agapov and colleagues also assessed expression levels for each of the potential chitinase and 
chitinase-like family members that may be found in human lung. In lung tissue obtained from COPD 
subjects, the authors could detect significantly increased levels of Chit1 compared to control subjects. 
In immunohistochemically stained lung sections, Chit1+ cells were found to be adjacent to IL-13+ 
cells. Interestingly, plasma chitinase 1 levels correlated strongly with decline in lung function (Agapov 
et al., 2009). Woodruff et al. observed an increased frequency of M2 alveolar macrophages in 
smokers, using MMP12 as a marker for alternative macrophage activation (Woodruff et al., 2005). In 
summary there is evidence for a role of M2 rather than for M1 macrophages in COPD pathogenesis. 
 The role of soluble inflammatory mediators in COPD 
Cytokines and chemokines that recruit, activate and promote survival of inflammatory cells in the 
respiratory tract are the main actors in causing chronic inflammation in COPD. More than 50 cytokines 
are known to be involved in COPD (Barnes, 2008), but their role remains often unclear. 
 Proinflammatory cytokines 
In the sputum and BAL fluid of COPD patients elevated levels of TNF-α, IL-1β and IL-6 are found.  
These proinflammatory cytokines amplify inflammatory processes, partly through the activation of 
NFκB which in turn causes the increased expression of a multitude of inflammatory genes (Barnes, 
2009). Many cells, such as macrophages, mast cells, T cells, epithelial cells, and airway smooth 
muscle cells, are capable to secrete TNF-α (Keatings et al., 1996). Since TNF-α is increased in COPD 
patients, particularly during exacerbations (Aaron et al., 2001), and is strongly involved in CS-induced 
emphysema in mice (Churg et al., 2004) it seems obvious that anti-TNF-α strategies may provide 
therapeutic options. However, infliximab (a chimeric antibody specific for human TNF-α) does not 
have any positive effects on symptoms, lung function, and exercise performance in patients with 
COPD in doses that are effective in individuals with rheumatoid arthritis (RA) (Rennard et al. 2007). 
IL-1β levels are markedly increased in the sputum of COPD patients and correlate with disease 
severity (Sapey et al., 2009). IL-1β in COPD patients stimulates macrophages to produce cytokines 
and chemokines as well as MMP9 (Culpitt et al., 2003). Clinical studies of a fully humanized IL-1β 
antibody (canakinumab) with more than 2000 COPD patients and healthy volunteers did not result in 
evidence-based findings that might support the use of IL-1β antibody therapy in the treatment of 
COPD(Rogliani et al., 2015). Furthermore, COPD patients show increased IL-6 concentrations in 
sputum, exhaled breath and plasma, particularly during exacerbations (Bhomik et al. 2000; Bucchioni 
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et al., 2003). Tocilizumab, an antibody that blocks IL-6 receptors and which has been successfully 
applied to treat RA and inflammatory bowel disease (IBD), has yet to be tested in COPD (Barnes, 
2009) . 
 Growth factors 
Certain cytokines contributing to pathological changes in COPD by either promoting inflammatory cell 
survival or differentiation or fostering the proliferation and/or activation of structural cells (Barnes, 
2009). One of the COPD-relevant growth factors is GM-CSF which is secreted mainly by 
macrophages, epithelial cells, and T cells in response to inflammatory stimuli. In COPD, GM-CSF is 
primarily secreted by alveolar macrophages and might contribute to increased survival of neutrophils 
and macrophages in the airways (Culpitt et al. 2003). There is a correlation between elevated GM-
CSF levels in BAL fluid of COPD patients and increased numbers of neutrophils, particularly during 
exacerbations (Balbi et al. 1997). Vlahos et al. demonstrated that neutralizing GM-CSF inhibited CS-
induced lung inflammation by reducing BAL neutrophils and macrophages as well as TNF-α, MIP-2 
and MMP12 mRNA expression (Vlahos et al., 2010). A further study blocking GM-CSF receptor also 
described attenuated neutrophil influx in CS-exposed mice (Botelho et al., 2011). 
 Chemokines 
In COPD chemokines induce chemotaxis of inflammatory cells from the circulation to the airways 
(Donnelly and Barnes 2006). CCL2 (Chemokine (C-C Motif) Ligand 2, also known as MCP-1) levels 
are increased in the sputum, BAL fluid, and lungs of patients with COPD. CCL2 is released by alveolar 
macrophages, T cells, and epithelial cells (de Boer et al. 2000; Traves et al. 2002). CCL2 activates 
CCR2 on monocytes and T cells (Deshmane et al., 2009)  and might be involved in the accumulation 
of macrophages in the lungs of COPD patients since it is an effective chemoattractant of monocytes. 
The chemokine receptor CCR5 binds CCL3 (also known as MIP-1α), CCL4 (also known as MIP-1β), 
and CCL5, all of them are upregulated in the lungs of individuals with COPD (Curtis et al., 2007; Fuke 
et al., 2004). The airways of patients with mild to moderate COPD (Stefano et al., 2001) and the 
sputum of patients with COPD show elevated numbers of CCR5 expressing T cells (Costa et al. 
2008). CXCL8 (also known as IL-8 with the murine homologue KC) interacts with CXCR1 and CXCR2, 
which also binds related CXC chemokines, such as CXCL1 (also known as GRO-α) (Baggiolini et al., 
1997). Increased CXCL1 and CXCL8 levels correlate with an increased proportion of neutrophils in 
induced sputum of patients with COPD (Keatings et al. 1996; Traves et al. 2002). Another CXC 
chemokine, CXCL13, mentioned above, is produced within lymphoid follicles of patients with COPD 
and is crucial for the formation of TLOs (Litsiou et al., 2013). Neutralization of CXCL13 partially 
protects mice against CS-induced inflammation in bronchoalveolar lavage and alveolar wall 
destruction (Bracke et al., 2013). 
 Anti-inflammatory cytokines 
As described above, most cytokines foster the inflammatory processes in COPD, though some 
cytokines have inhibitory or anti-inflammatory properties. IL-10, as an efficient anti-inflammatory 
cytokine, blocks the synthesis of certain cytokines, such as TNF-α and IL-1 (Cassatella et al., 1993; 
Moore et al., 1993) as well as several chemokines which are increased in COPD. Furthermore, IL-10 
inhibits antigen presentation (Ozawa et al. 1996). IL-10 might also have beneficial effects in COPD in 
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such a way that it impedes MMP-9 production. COPD patients exhibit reduced IL-10 levels in induced 
sputum samples (Takanashi et al.1999). 
 Matrix Metalloproteinases (MMP) 
MMPs are a large family of zinc-dependent proteinases which are important regulators of the 
extracellular matrix degradation (Stamenkovic 2003). There is rising evidence for an involvement of 
MMPs in the COPD pathogenesis (Shapiro 1999). Various polymorphisms of MMP-1, MMP-9, and 
MMP-12 have been linked to emphysema (Minematsu et al., 2001; Joos et al., 2002; Wallace and 
Sandford, 2002). The basic principle of the protease–antiprotease hypothesis is that alveolar wall 
matrix gets attacked by proteases secreted from CS-induced inflammatory cells, thus leading to 
emphysema (Shapiro, 2003). There is an increased interest in MMPs since it has been demonstrated 
that MMP-12-/- mice are protected against emphysema induction by chronic CS exposure (Hautamaki 
et al. 1997). Using a selective inhibitor to block the catalytic activity of MMP-12 in a 4-day acute model 
resulted in reduced lavage neutrophil numbers by about 50% and lavage macrophages by about 40%. 
This was accompanied by a reduction of soluble TNF receptors, MIP-1γ, IL-6, KC, CXCL1, CXCL11, 
tissue inhibitor of metalloproteinase (TIMP)-1 and pro-MMP-9 (Quement et al., 2008). Interestingly, 
CS-induced emphysema development is not prevented in MMP-9-/- mice, but they are protected 
against small airway fibrosis (Lanone et al. 2002).  
 Cigarette smoke induced experimental models 
 In vitro models of cigarette smoke exposure 
There are two currently used COPD-relevant models to study CS effects in vitro: the cigarette 
smoke extract (CSE) model and the whole cigarette smoke exposure model, or rather the smoking 
chamber model. 
Cigarette smoke extract model 
In this model, CS is generated by means of a smoking machine and the particulate matter is collected. 
Depending on the method there are different types of extracts that can be collected from CS. The 
most commonly used CS extracts are total particulate matter (TPM) and cigarette smoke condensate 
(CSC): 
• CSC is usually collected by condensing smoke components using impingers connected to the 
smoking machine. CS is passed into phosphate-buffered saline or culture medium as the 
aqueous solvent. The end-product of this method contains water-soluble components from 
both the particulate and gas/vapor phases of whole smoke. 
• CSC may also be collected using electrostatic precipitation 
• TPM is collected by transmitting CS through a Cambridge filter pad. The TPM gets trapped on 
the filter pad and is eluted using a solvent such as dimethyl sulfoxide (DMSO).  
Subsequently, CSC or TPM is diluted in a suitable diluent (e.g. culture medium) and cells are directly 
submerged in medium containing the CSE.  
Whole Smoke exposure 
In this model, cells are grown at the air-liquid interface and exposed to smoke directly, using a gas 
exposure chamber (Johnson et al., 2009). 
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 CS-induced COPD mouse models 
Human COPD consists of at least three anatomical lesions: emphysema (Colebatch et al., 1973; 
Penman et al., 1970), small airway remodeling (including goblet cell hyperplasia) (Hogg et al., 2004)    
and chronic bronchitis (Cosio et al., 1978). In COPD patients any of these features or all of them might 
be present. Furthermore, some COPD patients develop acute exacerbations (Burge and Wedzicha, 
2003; Celli and Barnes, 2007) and to make it even more complicated, COPD is slowly progressive 
over many years (Pauwels and Rabe, 2004). Animals used to model COPD should have a pulmonary 
anatomy similar to that of humans. In the best case the model should allow the investigator to mimic 
all the different lesions of COPD, listed above, during a short period of time. Unfortunately none of 
the so far described COPD animal models can meet all the listed criteria, but due to human to human 
variation a human patient would also not meet all of them (Wright et al., 2008). To date, many species 
have been used including rodents, dogs, guinea-pigs, monkeys, and sheep. Mice are the most 
suitable species to investigate pathogenic pathways of COPD, given the advances in genetic 
engineering, the abundance of information about the mouse genome and the variety of antibody 
probes (Mahadeva and Shapiro, 2002). Also advanced devices for pulmonary function tests enable 
measuring pressure-volume curves and compliance changes fairly easily in mice. With increasing 
length of CS exposure abnormalities in lung function progress, such as: increased residual volume, 
functional residual capacity, total lung capacity, compliance and decreased ratios of FEV/FVC (Wright 
and Churg, 1990). However, the lesions caused by CS in small laboratory animals can be only slight, 
even on a microscopic level; thus morphometric analysis is required to assess the degree of damage. 
For this purpose measurements of air space size (Lm) or surface-to-volume ratio (Sv) are used 
(Thurlbeck 1994).   
In mice characteristic features of human COPD can also be induced by exogenous administration of 
proteases, chemicals and particulates (Mahadeva and Shapiro, 2002). Given its role as the 
predominant cause of COPD, animal models using CS exposure appear to be the method of choice. 
Human features of COPD such as emphysema and small airway remodeling are covered by this 
model. Other characteristics such as mucus hypersecretion are more problematic. Another important 
disadvantage of these models is that the induction of either emphysema or small airway disease is 
an expensive and time-consuming process that takes up to 6 months (Tab.3). Next to the exposure 
duration, existing CS exposure models vary in the use of either mainstream smoke only or a mixture 
of side- and main-stream smoke (usually consisting of about 90% sidestream smoke and 10% 
mainstream smoke). However, the most important limitation of CS models, independent of the used 
species, the duration of smoke exposure and the composition of CS, is that only mild forms of COPD, 
probably equivalent to GOLD stage 1 or 2 can be induced (Wright et al., 2008).  
Table 3: Pros and cons of cigarette smoke-induced models of COPD 
Pros Cons 
Induced by the same insult as in humans Does not produces the severe disabling 
disease seen in humans 
Induces emphysema, airway remodeling, 
and vascular remodeling/pulmonary 
hypertension in selected species  
Requires several months of exposure 
Induces physiological alterations similar to 
humans 
Lesions do not appear to progress after 
cessation of cigarette smoke exposure 
(Adapted from Wright et al. 2008) 
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 Aim of the study 
It is well accepted that inflammatory processes play an important role in the pathogenesis of COPD. 
But until now precise mechanisms are not uncovered and anti-inflammatory agents such as 
corticosteroids, which are thought to improve obstructed airflow by decreasing the chronic 
inflammation, do not modify the long-term decline in lung function nor mortality. Thus, further studies 
are needed to identify the main contributing immune cells in order to develop more target-oriented, 
therapeutic approaches. 
This study aimed at describing the kinetics of inflammatory cell recruitment in response to acute 
sidestream and mainstream as well as chronic CS and in detail to identify how B cells contribute to 
these kinetics and subsequently to emphysema development. 
Therefore, we aimed at: 
 
1) characterizing the time depended recruitment of inflammatory cells in acute sidestream vs. 
mainstream CS exposure models and under chronic mainstream CS conditions; 
2) investigating whether B cells are required for the development of COPD pathogenesis; 
3) analyzing the mechanism of B cell-mediated pathogenic effects 
 
Due to its adverse health effects for non-smokers, not only mainstream smoke but also sidestream 
smoke, more precisely environmental tobacco smoke, mainly composed of exhaled mainstream 
cigarette smoke (CS) and sidestream CS, is under critical evaluation. Mainstream smoke, side stream 
smoke, and seconhand smoke (SHS), are nearly identical in their qualitive composition but the 
quantitative composition of each is different (Leberl et al., 2013). In the enclosed environment some 
compounds are emitted at up to tenfold increased levels in side stream smoke and SHS when 
compared with mainstream smoke (Moritsugu, 2007). Side stream smoke has therefore been 
classified as a Class A carcinogen by the US Environmental Protection Agency (U.S. Environmental 
Protection Agency 1992). We initially performed a comparison of the dynamics of acute lung 
inflammation between the acute main- and sidestream CS model. Acute CS exposure models are 
used to study more direct and early responses to CS. It is now generally accepted that inflammatory 
responses in CS exposure models proceed in two phases: an acute reaction during the first week of 
exposure accompanied by an influx of neutrophils and a progressive inflammation after one month of 
CS exposure consisting of neutrophils, macrophages and lymphocytes (D’hulst et al., 2005; 
Stevenson et al., 2007; Wan et al., 2010). Several studies have shown that innate immune cells of 
CS-exposed mice are sufficient for driving inflammatory processes in the lung subsequently initiating 
COPD like changes (D’hulst et al., 2005a; Stevenson et al., 2007; Wan et al., 2010). These studies 
suggest the importance of acute CS models to study prompt CS induced inflammatory mechanisms 
and immune cell activation that potentially contribute to COPD pathogenesis in an early stage of CS 
exposure. Interestingly, until now mainly mainstream smoke models were used to investigate acute 
CS induced responses. The only acute sidestream study analyzed oxidative DNA damage in mouse 
heart, liver and lung tissue after a single CS exposure (Howard et al., 1998). Time- and dose-
dependent inflammatory responses after acute mainstream CS exposure have already been 
described (Morris et al., 2008; Stevenson et al., 2005; Vlahos et al., 2006). But until now, no 
comprehensive comparison of the dynamics of acute inflammatory processes in the lung between 
main- and sidestream CS exposure has been performed. Additionally, based on the results of the 
acute study the mainstream CS model was chosen as the more suitable model for chronic CS 
exposure studies. 
In chronic CS exposure experiments, we monitored functional and structural changes such as lung 
function decline and loss of alveolar structures in a time-dependent manner and related these 
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changes to the CS-induced inflammatory kinetics. Since chronic CS exposure leads to the 
accumulation of B cells organized in iBALT structures, as well as macrophages in the lungs, which 
might contribute to CS-induced emphysema, we focused on these two immune cell types. By 
exposing B cell depleted mice to CS we demonstrated that these mice are protected against 
emphysematous changes. In further experiments this study aimed at investigating the mechanisms 
by which B cells account for COPD development. We hypothesized that antibody-independent 
functions of B cells such as their organization in iBALT structures and manipulating other immune 
cells via the secretion of soluble mediators might be more important with regard to COPD than their 
antibody-producing capacity. Here, B cells have been shown to influence macrophage polarization 
towards a phenotype characterized by increased MMP12 production. Thus we hypothesized that CS-
induced B cells might cause macrophage accumulation and macrophage-derived MMP12 secretion.  
 Research project  
The essential methodic tools to examine the dynamics of immunological cells and in more detail the 
role of B cells in the development of COPD in a CS induced COPD mouse model comprise primarily 
the COPD mouse model per se. Furthermore, methods to analyze mouse lung function and to 
quantitatively evaluate morphological changes in lung tissue as well as immunological, molecular and 
histological methods are required. The analysis of lymphocyte populations and their activation state 
by flow cytometry and the identification of relevant mediators on mRNA and protein level have been 
the focus of the study. 
 Cigarette smoke induced COPD mouse model 
For the accomplishment of the presented studies, a CS-induced COPD mouse model was used. 
Despite the cons listed in Table 1, this model was used due to the facts that both active and second 
hand CS represent the main risk factors for COPD development, and that CS-induced pathological 
alterations seen in the experimental mouse model are close to those observed in COPD patients. For 
the here presented studies pathogen-free C57BL/6 and B cell deficient B6.129S2-Igh-6tm1Cgn/J mice 
(also µMT mice) were used. All mice were housed in rooms maintained at constant temperature and 
humidity. A 12 hour light/dark cycle was maintained and mice had access to food and water ad libitum. 
All procedures involving animals were approved by the by the local government for the administrative 
region of Upper Bavaria and were conducted under strict governmental and international guidelines. 
Mice were exposed to CS-generated from 3R4F Research Cigarettes (Tobacco Research Institute, 
University of Kentucky, Lexington, KY). Control mice for all experiments were kept in a filtered air 
environment.  
The machine is adjusted to produce 89% sidestream and 11% mainstream smoke. The chamber 
atmosphere was monitored to maintain total particulate matter (TPM) at 250 and 500 mg/m³ and mice 
were exposed to CS for 50 min twice per day for 3 consecutive days. 
To mimic natural human smoking habits the mainstream CS model was used and mice were exposed 
to active smoke (100% mainstream smoke). The smoke was drawn into the exposure chamber via a 
membrane pump. Just as in the sidestream model, mice were exposed to CS of 250 and 500 mg/m3 
TPM for 50 min twice per day for 3 consecutive days as described by Eltom et al. (Eltom et al. 2011). 
For chronic CS exposure the mainstream model was used. Mice were exposed to a TPM of 500mg/m3 
for 50 min twice per day, 5 days a week, for up to 6 months. Mice were analyzed after 2, 4 and 6 
months of CS exposure, 24h after the last exposure. 
To determine TPM concentrations sample air from the exposure chamber was collected on quartz 
fiber filters and the total air volume was measured. Via gravimetric analysis of the filters prior and after 
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exposure TPM mass concentration was obtained (estimated accuracy of approximately 5%). A GCO 
100 CO Meter (Greisinger Electronic, Regenstauf, Germany) was used to constantly monitor CO 
concentrations in the exposure chamber. To measure levels of arterial blood carboxyhemoglobin (CO-
Hb) in mice 30 min after CS exposure retro-orbital blood samples were analyzed in an ABL80 FLEX 
blood gas analyzer (Radiometer, Willich, Germany). All acute CS exposure experiments were 
performed with n=6, chronic CS exposure experiments were performed with n=4 animals per group 
and all experiments were repeated twice. 
 Lung function measurement  
 
For lung function testing anesthetized mice were tracheostomized and connected to the FlexiVent 
system (Emka, France). The mice were ventilated with a tidal volume of around 10mg/kg at a 
frequency of 150 breaths/min to reach a mean lung volume similar to that of spontaneous breathing. 
Measurement of lung mechanical properties was started by a computer generated program to 
measure dynamic lung compliance and resistance. These measurements were repeated four times 
for each animal. 
 Quantitative morphometry and immunohistochemistry  
 
By default two histopathological aspects of COPD have been analyzed using the right mouse lung: 1) 
airway inflammation with infiltration of neutrophils, macrophages and lymphocytes, 2) development of 
emphysema with increased mean chord length. Design-based stereology was used to analyze the 
lung sections. In this connection, samples have to be treated in a standardized way (‚systematic 
uniform random sampling‘) to ensure that tissue samples, slides and finally the microscopic view fields 
which are included in the analysis are representative for the entire organ independent of the properties 
of the investigated structures.  
Quantitative determination of lymphocyte subsets and other immune cells was performed by 
immunohistochemical staining of paraffin slides. Therefore, the so-called ‚physical-dissector‘ method 
(sections with a known distance from each other) has to be used to allow serial sections. The 
localization and total number of lymphocytes or macrophages was determined by staining with the 
particular cell-specific antibody, CD45R for B cells, CD3 for T cells and MMP12 for macrophages. 
The quantitative analyses were performed using an Olympus BX51 light microscope equipped with 
the computer-assisted stereological toolbox newCAST of Visiopharm. 
 Molecular biology 
 
The aim of the molecular studies was to carry out a screening for differentially expressed pro- and 
anti-inflammatory genes in CS exposed Wt vs. CS exposed µMT mice and in control mice. 
Furthermore, the time-dependent appearance of certain cellular mediators in various lung 
compartments during COPD development should be determined. For this purpose, the left lung was 
shock-frozen in liquid nitrogen for protein and RNA analysis. Expression analysis of the target 
parameters was performed at the mRNA level by quantitative real-time RT-PCR and on protein level 
by Western Blot.  
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 Analysis of immunological parameters  
To monitor immunological parameters in different compartments, a variety of techniques was 
established. These include: the analysis of lymphocyte subsets and their activation status, the 
detection of inflammatory mediators as well as differential cell analysis of BAL. Using flow cytometry 
analysis, lymphocyte subsets in mouse lung tissue have been characterized during the duration of 
CS exposure. Concentrations of inflammatory mediators were quantified by magnetic bead-based 
multiplex protein assays. These allow the simultaneous determination of multiple analytes in a small 
sample volume of cell supernatant or BAL using specific capture antibodies, which are coupled to 
dual-color labeled beads. The analysis of the beads is carried out by a dual-laser flow-based detection 
instrument (Luminex® 100/200™ System). One laser excites the internal dyes defining the bead sets 
and a second laser excites PE, the fluorescent dye on the reporter molecule.  
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2 Zusammenfassung 
Die chronisch obstruktiven Lungenerkrankungen (COPD) stellen ein globales Gesundheitsproblem 
mit steigender Prävalenz, Morbidität und Mortalität dar. Die WHO prognostiziert für COPD im Jahr 
2020 Rang drei der häufigsten Todesursachen weltweit. COPD ist charakterisiert durch eine 
progressive, nicht vollständig reversible Verschlechterung der Lungenfunktion welche durch die 
Entstehung des Emphysems und den Umbau der Atemwege bedingt ist. Anormale entzündliche 
Reaktionen der Lunge auf gesundheitsschädliche Partikel oder Gase werden mit diesen 
pathologischen Veränderungen assoziiert. Der Hauptrisikofaktor in den Industrieländern stellt das 
Rauchen dar. Gegenwärtig existiert keine heilende Therapie für COPD, die Behandlung zielt lediglich 
auf die Linderung der Symptome ab.  
Chronischer Zigarettenrauch führt in der Lunge zu einer anormalen Entzündungsantwort, welche 
sowohl Zellen des angeborenen Immunsystems wie Neutrophile und Makrophagen als auch Zellen 
der adaptiven Immunität wie B- und T-Lymphozyten einschließt. Interessanterweise konnten wir in 
unserer ersten Arbeit zeigen dass die Dynamik der Rekrutierung von Entzündungszellen in die Lunge 
stark von der Zusammensetzung des Zigarettenrauchs abhängt. Es wurden hierbei die 
Entzündungsreaktionen als Antwort auf Zigarettenrauch unter Aktiv- und Passivrauchbedingungen 
verglichen. Wildtyp Mäuse wurden zwei Konzentrationen (250 und 500mg/m3 Rohkondensat) Aktiv- 
oder Passivrauch für 3 Tage ausgesetzt. Wir beobachteten eine starke Entzündungsreaktion, 
gekennzeichnet durch einen Neutrophileneinstrom, einer vermehrten Zytokinsezernierung (KC, 
MIP1a, MCP1, TNFa, MIP2), einer erhöhten proinflammatorischen Genexpression (KC, MIP2, 
MMP12) und einer hochregulierten GM-CSF-Produktion im Aktivrauchmodell. Das 
Passivrauchmodell erzeugte hingegen eine verminderte Entzündungsantwort, gekennzeichnet durch 
das dominierende Auftreten von Makrophagen und dem Fehlen von Neutrophilen sowie der 
verringerten GM-CSF-Produktion, höchstwahrscheinlich verursacht durch erhöhte CO-
Konzentrationen unter Passivrauchbedingungen. Um für die chronische Zigarettenrauchexposition 
von Mäusen einen negativen Effekt der höheren CO-Konzentrationen auszuschließen, wurden für 
das chronische Modell Aktivrauchbedingungen verwendet. Chronische Zigarettenrauchexposition 
führt in Mäusen besonders zu einer Akkumulation von B-Zellen, organisiert in iBALT Strukturen, und 
Makrophagen in der Lunge. Die Frage nach deren möglicher Beteiligung an der Entstehung des 
Emphysems war Inhalt unserer chronischen Studie. Wir haben gezeigt, dass bis zu sechs Monate 
Zigarettenrauch exponierte B-Zell defiziente Mäuse gegenüber Wildtyp (Wt) Mäusen vor der 
Entwicklung COPD-ähnlicher Veränderungen geschützt sind. Verglichen mit µMT Mäusen wiesen Wt 
Mäuse nach chronischer Zigarettenrauchexposition deutliche lymphoide Strukturen (iBALT) auf, 
sowie eine signifikante Verschlechterung der Lungenfunktion und einen signifikanten Verlust 
alveolärer Septen. Die erhöhte Akkumulation von lungenansässigen Makrophagen um die iBALT 
Strukturen herum und in den alveolären, emphysematösen Bereichen in zigarettenrauchexponierten 
Wt Mäusen war assoziiert mit einer signifikant stärkeren MMP12 Expression. Anschließende in vitro 
- Co-Kultur- Experimente unter Verwendung von B -Zellen und Makrophagen zeigten, dass von B-
Zellen sezerniertes IL-10 die Makrophagenaktivierung und MMP12 Expression induziert. 
Zusammenfassend konnte gezeigt werden dass Antikörper-unabhängige Funktionen von B-Zellen in 
der iBALT Formation von Bedeutung für die Makrophagen-induzierte Gewebezerstörung in 
Zigarettenrauch-vermittelter Emphysementstehung sind. Daraus ergibt sich möglicherweise ein 
Angriffsziel für neue therapeutische Ansätze. 
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3 Summary  
Chronic obstructive pulmonary disease (COPD) represents a global health problem with increasing 
prevalence, morbidity and mortality. The WHO ranked COPD the third common cause of death 
worldwide by 2020. COPD is characterized by a progressive and not fully reversible impairment of 
lung function which is caused by the development of emphysema and remodeling of the airways. 
Abnormal inflammatory responses of the lungs to noxious particles or gases are associated with these 
pathological changes. In developed countries the main risk factor is smoking. Currently there is no 
curative therapy for COPD; treatment may only aim to alleviate symptoms.  
Chronic cigarette smoke leads to an abnormal inflammatory response in the lungs, which includes 
cells of both the innate immune system such as neutrophils and macrophages, as well as cells of the 
adaptive immunity, such as B- and T-lymphocytes. Interestingly, we have shown in our first study that 
the dynamics of the inflammatory cell recruitment to the lung strongly depends on the composition of 
cigarette smoke. In this connection, inflammatory responses to either mainstream smoke or 
sidestream smoke were compared. Mice were exposed to two concentrations (250 and 500 mg/m3 
total particulate matter) sidestream and mainstream cigarette smoke for 3 days. We observed a strong 
inflammatory response characterized by a neutrophilic influx, an increased cytokine secretion (KC, 
TNFa, MIP1a, MCP1, MIP2), elevated pro-inflammatory gene expression (KC, MIP2, MMP12) and 
an up-regulated GM-CSF production in the mainstream model. However, the sidestream CS model 
induced a dampened immune reaction lacking neutrophils and consisting only of macrophages and 
impaired GM-CSF production, most likely caused by higher CO levels under sidestream CS 
conditions. In order to exclude negative effects of high CO concentrations in chronically CS exposed 
mice, mainstream smoke conditions were used for the chronic exposure model. Chronic CS exposure 
of mice leads to the accumulation of B cells organized in iBALT structures, as well as macrophages 
in the lungs. This might contribute to CS-induced emphysema, but the mechanisms thereof remain 
unclear. We have shown that up to six months cigarette smoke-exposed B-cell deficient mice 
compared to Wt mice are protected against the development of COPD-like changes. In contrast to 
µMT mice chronically CS exposed Wt mice exhibited significant lymphoid structures (iBALT), a 
significant decline of lung function and a significant loss of alveolar septa. The increased accumulation 
of lung resident macrophages surrounding the iBALT structures and in the alveolar, emphysematous 
areas in CS exposed Wt mice was associated with a significantly increase of MMP12 expression. In 
following in vitro experiments, it could be shown that cigarette smoke extract stimulated B cells to 
secrete IL-10 and IL-10 containing B-cell supernatants in turn induced MMP12 expression in 
macrophages. This up-regulated MMP12 expression was inhibited by the addition of an IL-10-
neutralizing antibody. In summary, our data highlight that CS exposure leads to B cell-dependent 
iBALT formation, which contributes to the pathogenesis of COPD via IL-10-induced macrophage 
activation and MMP12 up-regulation. This mechanism maintains the severe inflammatory response 
causing subsequent emphysema development in COPD. The link between innate and adaptive 
immune cell responses to CS in COPD is of great clinical relevance and could be explored as a target 
for therapeutic intervention in COPD patients. 
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Abstract
COPD (chronic obstructive pulmonary disease) is caused by exposure to toxic gases and particles, most often CS
(cigarette smoke), leading to emphysema, chronic bronchitis, mucus production and a subsequent decline in lung
function. The disease pathogenesis is related to an abnormal CS-induced inflammatory response of the lungs.
Similar to active (mainstream) smoking, second hand (sidestream) smoke exposure severely affects respiratory
health. These processes can be studied in vivo in models of CS exposure of mice. We compared the acute
inflammatory response of female C57BL/6 mice exposed to two concentrations [250 and 500 mg/m3 TPM (total
particulate matter)] of sidestream and mainstream CS for 3 days and interpreted the biological effects based on
physico-chemical differences in the gas and particulate phase composition of CS. BAL (bronchoalveolar lavage fluid)
was obtained to perform differential cell counts and to measure cytokine release. Lung tissue was used to
determine mRNA and protein expression of proinflammatory genes and to assess tissue inflammation. A strong
acute inflammatory response characterized by neutrophilic influx, increased cytokine secretion [KC (keratinocyte
chemoattractant), TNF-α (tumour necrosis factor α), MIP-2 (macrophage inflammatory protein 2), MIP-1α and MCP-1
(monocyte chemoattractant protein-1)], pro-inflammatory gene expression [KC, MIP-2 and MMP12 (matrix
metalloproteinase 12)] and up-regulated GM-CSF (granulocyte macrophage colony-stimulating factor) production was
observed in the mainstream model. After sidestream exposure there was a dampened inflammatory reaction
consisting only of macrophages and diminished GM-CSF levels, most likely caused by elevated CO concentrations.
These results demonstrate that the composition of CS determines the dynamics of inflammatory cell recruitment in
COPD mouse models. Different initial inflammatory processes might contribute to COPD pathogenesis in
significantly varying ways, thereby determining the outcome of the studies.
Key words: chronic obstructive pulmonary disease (COPD), inflammation, mainstream, neutrophil, sidestream, smoke
INTRODUCTION
COPD (chronic obstructive pulmonary disease) is a major public
health problem and its morbidity and mortality are still rising [1].
Patients suffering from COPD exhibit a constant and accelerated
decline in lung function leading to airflow limitation. The patho-
Abbreviations: BAL, bronchoalveolar lavage; CC, carbonyl compounds; CMD, count median diameter; CO-Hb, carboxyhaemoglobin; COPD, chronic obstructive pulmonary disease; CS,
cigarette smoke; DNPH, 2,4-dinitrophenylhydrazine; GC-SIM-MS, gas-chromatography with selective ion monitoring MS; GM-CSF, granulocyte macrophage colony-stimulating factor; HO,
haem oxygenase; H&E, haematoxylin and eosin; HPRT-1, hypoxanthine–guanine phosphoribosyltransferase; IFNβ, interferon β; IL-1β, interleukin 1β; KC, keratinocyte chemoattractant;
LPS, lipopolysaccharide; MCP-1, monocyte chemoattractant protein-1; MIP, macrophage inflammatory protein; MMD, mass median diameter; MMP12, matrix metalloproteinase 12; NE,
neutrophil elastase; NF-κB, nuclear factor κB; PAH, polycyclic aromatic hydrocarbons; PM, particulate matter; TNF-α, tumour necrosis factor α; TPM, total particulate matter.
Correspondence: Dr Ali O¨nder Yildirim (email oender.yildirim@helmholtz-muenchen.de).
genesis of COPD is characterized by severe pathophysiological
changes including chronic bronchitis, small airway remodelling,
mucus production and the development of emphysaema [2]. How-
ever, the exact processes involved in disease pathogenesis are so
far not fully understood and treatment can only aim at alleviating
symptoms.
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CS (cigarette smoke) is a major etiologic factor in the patho-
genesis of COPD and other diseases [3]. The health impact of
environmental CS is under critical evaluation, due to the risk
for non-smokers. Environmental CS is mainly composed of ex-
haled mainstream CS and sidestream CS, whereby the impact of
sidestream CS with respect to environmental CS surpasses that
of exhaled mainstream CS [4]. Chronic CS exposure results in
severe lung inflammation by initiating a complex inflammatory
cascade accompanied by the activation and influx of various in-
flammatory cells and by the secretion of disease-specific mediat-
ors such as cytokines and growth factors [5]. The smoke-induced
increase in inflammatory cell influx and responses involves both
innate immune cells, with macrophages and neutrophils predom-
inating, and adaptive immune cells, specifically T and B lymph-
ocytes. The numbers of neutrophils, macrophages and lympho-
cytes are increased in both airways and parenchyma of patients
with COPD [6–9]. The progression and severity of COPD are
also associated with increasing infiltration of the airways by in-
nate and adaptive immune cells, leading to obstruction of small
airways and thickening of the airway wall [10]. Nevertheless, it
still remains unclear that inflammatory events and cell types in-
volved in this complex cascade are central for the development
of COPD.
In order to elucidate these processes in vivo, CS exposure of
rodents/mice is a commonly used model. Chronic exposure, that
is, up to 4 months or longer, recapitulates most features of COPD
by inducing pathophysiological changes in mice similar to those
observed in COPD patients, such as small airway remodelling
and septal tissue damage/emphysaema. On the other hand, acute
CS exposure is mostly useful and employed to study early and
more direct effects of smoking on inflammatory responses and
cell recruitment in the lung, specifically innate immune cells [11].
Several animal studies have analysed the contribution of
neutrophils and macrophages to CS-induced lung inflammation
and subsequent emphysema development. It is now generally ac-
cepted that in CS models the inflammatory response driving the
pathophysiological changes is characterized by two phases:
the acute reaction during the first week of CS exposure, which
shows a strong neutrophilic influx, and the progressive inflam-
mation after 1 month of exposure consisting of neutrophils, mac-
rophages and lymphocytes [12–14]. Interestingly, it was shown
that in CS-exposed mice innate immune cells were sufficient
for driving inflammatory processes in the lung thereby initiating
COPD development [15,16]. Innate immune cell-specific factors
MMP (matrix metalloproteinase) 12 and NE (neutrophil elastase)
were even necessary for inducing experimental emphysema after
prolonged exposure [17,18]. Although CS-exposed MMP12-
knockout mice failed to recruit macrophages and did not develop
lung destruction [17], NE was required for neutrophil and
monocyte recruitment as well as for the activation of MMP12
after CS exposure [18]. These studies highlight the importance
of prompt CS-induced inflammatory mechanisms and innate
immune cell activation that potentially contribute to COPD
pathogenesis at an early stage of smoke exposure.
However, different smoke exposure models with regards to
machines and setups using either mainstream smoke only or a
mixture of side- and main-stream smoke (usually consisting of
about 90 % sidestream smoke and 10 % mainstream smoke) have
been established and might generate varying results, especially
when comparing the degree of CS-induced changes [19]. The
dynamics of early lung immune cell reactions to CS was charac-
terized using the mainstream model in acute settings of smoke
exposure for a few days [20–22]. But even though sidestream CS
is more toxic than mainstream CS [23], data on acute lung inflam-
mation from this model are missing. The only acute sidestream
study investigated oxidative DNA damage in mouse heart, liver
and lung tissue after a single CS exposure [24].
Interestingly, time- and dose-dependent inflammatory re-
sponses after acute mainstream CS exposure have already been
described [20–22]. However until now, no study has ever per-
formed a comprehensive comparison of the dynamics of acute
lung inflammation between the main- and side-stream CS model
with regards to physico-chemical characteristics of CS, specific-
ally concentration, size distribution and chemical composition of
TPM (total particulate matter) as well as composition of the gas
phase.
Therefore using two different experimental models of smoke
exposure (mainstream and sidestream CS) with two TPM concen-
trations, the present study aimed at investigating the effect of the
physico-chemical characteristics of CS on the acute inflammat-
ory response in the lungs of mice after 3 days of CS exposure. We
hypothesized that early signs of inflammation would be appar-
ent, but significantly different between the two types of CS. The
results were interpreted based on detailed information on con-
centration, size distribution and chemical composition of TPM
as well as on CO concentration.
Interestingly, a strong acute inflammatory response charac-
terized by neutrophilic influx, accompanied by increased cy-
tokine secretion and pro-inflammatory gene expression, and up-
regulated GM-CSF (granulocyte macrophage colony-stimulating
factor) production was only observed in the mainstream CS
model, whereas there was a dampened inflammatory reaction
after sidestream exposure, most probably caused by elevated CO
concentrations.
MATERIALS AND METHODS
Animals and maintenance
Pathogen-free female C57BL/6 mice (8–10-weeks old) were ob-
tained from Charles River and housed in rooms maintained at
constant temperature and humidity with a 12 h light cycle. An-
imals were allowed food and water ad libitum. All animal ex-
periments were conducted under strict governmental and inter-
national guidelines and were approved by the local government
for the administrative region of Upper Bavaria.
CS exposure and CO monitoring
For both exposure models, smoke was generated from 3R4F Re-
search Cigarettes (Tobacco Research Institute, University of Ken-
tucky, Lexington, KY, U.S.A.). Control mice for all experiments
were kept in a filtered air environment.
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For sidestream CS exposure, mice were placed in an expos-
ure chamber connected to a TE-10 smoking machine (Teague
Enterprises). The machine is adjusted to produce 89 % sidestream
and 11 % mainstream smoke. The chamber atmosphere was mon-
itored to maintain TPM at 250 and 500 mg/m3 and mice were
exposed to CS for 50 min twice per day for 3 consecutive days.
In the mainstream CS model, mice were exposed to active
smoke (100 % mainstream smoke) in a manner mimicking natural
human smoking habits. The smoke was drawn into the exposure
chamber via a membrane pump. Mice were exposed to CS of 250
and 500 mg/m3 TPM for 50 min twice per day for 3 consecutive
days as described by Eltom et al. [25].
TPM concentrations were monitored by drawing sample air
from the exposure chamber through a quartz fibre filter and meas-
uring the total air volume. The TPM mass concentration was
obtained via gravimetric analysis of the filters prior to and after
exposure (estimated accuracy of approximately 5 %). CO con-
centrations in the exposure chamber were constantly monitored
by using a GCO 100 CO Meter (Greisinger Electronic). Levels of
arterial blood CO-Hb (carboxyhaemoglobin) in mice 30 min after
CS exposure were determined by retro-orbital blood sampling and
analysed in an ABL80 FLEX blood gas analyser (Radiometer).
All CS exposure experiments were performed with n= 6 animals
per group and were repeated twice.
CS particle size measurements
The size distribution of the PM (particulate matter) of CS was
measured during exposure experiments according to the same
protocol as described above, but without mice in the exposure
chamber. Sample air was drawn from the sampling port of the ex-
posure chamber (located in the centre near the top of the chamber)
and delivered at 0.75 l/min through 3 m of tubing to a scanning
mobility particle sizer (SMPS, TSI, Model 3080, TSI) in combin-
ation with a CPC (condensation particle counter; Model 3025,
TSI). The excess air was resupplied into the exposure system
downstream of the exposure chamber. The SMPS is a standard
aerosol sizer with a sizing accuracy of up to 2 % (here approxim-
ately 5 %), which measures the size of aerosol particles based on
their velocity (mobility) in an electric field [26]. To avoid poten-
tial measurement biases because of high particle concentration
and high CO/CO2 concentrations, the sample air was diluted by a
factor of 650 and 400 for the mainstream and sidestream condi-
tions respectively [27]. The SMPS was operated at a sample and
sheath flow rate of 0.3 and 1.5 l/min respectively, and the inertial
impactor at the inlet of the SMPS was removed to obtain an upper
sizing limit of 1000 nm (lower sizing limit, 23 nm). An entire size
distribution was obtained within 3 min. For quality assurance,
the particle sizing accuracy of the SMPS was verified with size-
certified reference particles (230 and 506 nm) and filtre samples
were taken for gravimetric analysis of aerosol mass concentra-
tions. For each of the four investigated cases (sidestream and
mainstream at 250 and 500 mg/m3) 3–5 size distributions were
recorded and averaged, since no significant trends were observed
after a short equilibration phase of a few minutes. The measured
number size distributions between 23 and 1000 nm were conver-
ted into length, surface area and mass-weighted size distributions
(density of 1 g/cm3) and the data were fitted simultaneously on all
four moments (number, length, surface area and mass) assuming
a lognormal shape with constant geometric standard deviation.
Since the median diameters of these moments are directly related
by the Hatch–Choate moment conversion equations, this proced-
ure enhances measurement accuracy especially near the upper
size range, where a part of the size distribution was outside of the
detection limit of the SMPS [28].
Analysis of organic PM compounds in mainstream
and sidestream CS
For organic analyses of the PM of CS, approximately 25 litres of
sample air were drawn from the exposure chamber and PM was
collected on quartz fibre filters (T293, 25 mm diameter; Munk-
tell). Prior to sampling, the filters were tempered at 500 ◦C for at
least 12 h.
The samples were analysed by using a newly developed in-situ
derivatization and thermal desorption method, which is coupled
to GC-MS (gas-chromatography with mass selective detection)
[29]. An internal standard mixture (isotope labelled compounds)
was spiked on a filter punch (3 mm diameter) prior to analysis
for quantification.
Gas phase analysis of CC (carbonyl compounds) in
mainstream and sidestream CS
Carbonyl emissions in the gas phase of CS were sampled using
high sample volume DNPH (2,4-dinitrophenylhydrazine) cart-
ridges (Sigma–Aldrich). Parallel samples were collected for each
CS type with different flow rates starting form 0.16 to 1.2 l/min
using critical nozzles connected to a vacuum pump.
CCs were assessed by GC-SIM-MS (gas-chromatography
with selective ion monitoring MS) using DNPH derivatization.
Prior to analysis, the cartridges were eluted with 1 ml of acetoni-
trile and samples were injected into the GC-SIM-MS system for
quantitative measurements.
Animal preparation
At 24 h after the last CS exposure, mice were killed with an
overdose of ketamine/xylazine followed by exsanguination. Mice
were dissected and BAL (bronchoalveolar lavage) was obtained
to perform total and differential cell counts for inflammatory
cell recruitment of neutrophils, macrophages and lymphocytes.
BAL fluid was used to evaluate cytokine secretion via multiplex
analysis. Lung tissue was either shock-frozen in liquid nitrogen
to determine tissue mRNA expression or fixed by intratracheal
instillation of PBS-buffered 6 % (v/v) PFA (paraformaldehyde)
and embedded into paraffin for H&E (haematoxylin and eosin)
staining.
Preparation of BAL
The lungs were lavaged by using a cannula inserted into the
trachea and instilling the lungs with 4×0.5 ml aliquots of sterile
PBS (Gibco). For cytospins, cells were spun down at 400 g and
resuspended in RPMI 1640 medium containing 10 % (v/v) FBS
(both from Gibco). Total cell counts were determined in a hemo-
cytometer via Trypan Blue exclusion. Maximally 1–2 % Trypan
Blue-positive cells were detected in both filtered air and CS-
exposed animals from the two CS models. Differential cell counts
www.clinsci.org 209© 2014 The Author(s)
The author(s) has paid for this article to be freely available under the terms of the Creative Commons Attribution Licence (CC-BY) (http://creativecommons.org/licenses/by/3.0/)
which permits unrestricted use, distribution and reproduction in any medium, provided the original work is properly cited.
G. John and others
Table 1 Primers used for quantitative real-time PCR of lung tissue
Gene Forward primer (5′→3′) Reverse primer (5′→3′)
HPRT-1 CCTAAGATGAGCGCAAGTTGAA CCACAGGACTAGAACACCTGCTAA
KC (CXCL1) CCGAGTCATAGCCACAC GTGCCATCAGAGCAGTCT
TNF-α CACCACGCTCTTCTGTCT GGCTACAGGCTTGTCACTC
MIP-2 (CXCL2) CTGTTGTGGCCAGTGAAC GCCCTTGAGAGTGGCTAT
MMP12 TGTACCCCACCTACAGATACCTTA CCATAGAGGGACTGAATGTTACGT
CD68 CCTCCACCCTCGCCTAGT C TTGGGTATAGGATTCGGATTTGA
GM-CSF GCCATCAAAGAAGCCCTG GCGGGTCTGCACACATGTTA
were performed using morphological criteria on May–Gru¨nwald–
Giemsa-stained cytospins (200 cells/sample).
Quantitative real-time RT (reverse
transcription)-PCR
Total RNA from lung tissue homogenate was isolated using
a peqGOLD Total RNA Kit (Peqlab) according to the manu-
facturer’s instructions. cDNA was synthesized using Random
Hexamers and MuLV Reverse Transcriptase (Applied Biosys-
tems). mRNA expression of target genes KC (keratinocyte
chemoattractant; CXCL1), TNF-α (tumour necrosis factor α),
MIP-2 (macrophage inflammatory protein 2) (CXCL2), MMP12,
CD68 and GM-CSF in comparison with housekeeping con-
trol HPRT-1 (hypoxanthine–guanine phosphoribosyltransferase
1) was determined using Platinum SYBR Green qPCR Super-
Mix (Applied Biosystems) on a StepOnePlusTM 96 well Real-
Time PCR System (Applied Biosystems). The primers used are
listed in Table 1. Relative transcript expression of a gene is given
as 2−Ct (Ct =Cttarget −Ctreference ), relative changes compared
with control are 2−Ct values (Ct =Cttreated −Ctcontrol ).
Primers were generated using Primer-BLAST software [30].
Multiplex cytokine analysis
Concentrations of secreted cytokines and chemokines IL-1β
(interleukin 1β), IL-2, IL-4, IL-5, IL-6, IL-7, IL-9, IL-10, IL-
13, IL-17A, GM-CSF, KC (CXCL1), TNF-α, IFNβ (interferon
β), MCP-1 (monocyte chemoattractant protein-1; CCL2), MIG
(monokine induced by interferon-γ ; CXCL9), MIP2 (CXCL2)
and MIP-1α (CCL3) in BAL were determined using a magnetic
bead-based MILLIPLEX MAG multiplex assay (Millipore) and
analysed on a Luminex100 (Bio-Rad Laboratories). For this assay,
BAL fluid was concentrated (10×) by ultrafiltration in Amicon
Ultra-0.5 centrifugal filter devices (Millipore).
Statistics
Results are given as mean values+− S.D. One-way ANOVA fol-
lowing Bonferroni post-hoc test was used for all studies with
more than two groups, if equal variances and normal distribution
was given. Student’s unpaired t test was performed to compare
the concentration of particulate organic compounds [PAHs (poly-
cyclic aromatic hydrocarbons) and alkanes] between two differ-
ent TPMs. Analyses were conducted using GraphPad Prism 6
software (GraphPad Software).
Figure 1 Measured number (A) and mass-based size distribu-
tion (B) of CS particles in the exposure chamber at a TPM of
250 mg/m3 for both sidestream (square) and mainstream CS
(triangle)
The symbols represent the measured values and the solid lines repres-
ent the corresponding lognormal curve fit of the data. CMD and MMD of
the size distributions are also depicted. The size distributions were nor-
malized to their respective total number and total mass concentration.
RESULTS
Sidestream CS particles are smaller in size than
mainstream CS particles
The size distribution of the PM of CS was determined using an
SMPS. Figure 1 depicts the number- and mass-weighted particle
size distribution for sidestream and mainstream conditions for a
mass concentration of 250 mg/m3. A summary of all size distri-
bution data is presented in Table 2.
Sidestream CS particles exhibited a CMD (count median dia-
meter) of 154 nm and were therefore significantly smaller than
mainstream CS particles (CMD= 313 nm) (Figure 1A). The geo-
metric standard deviation (width of the size distribution) was
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Table 2 Overview of characteristic parameters of the cigarette smoke size distributions for sidestream and mainstream
conditions
Mtot, mass concentration of total particulate matter in the smoke chamber; σ g, geometric S.D. *The reported alveolar lung
deposited fraction refers to the specific MMD and is based on in silico lung deposition data for mice published by Nadithe et
al. [31]. **A breathing frequency of 150/min and a tidal volume of 200 μl were assumed, resulting in an inhaled air volume
of 1.8 l/h.
Sidestream Mainstream
Parameter Mtot (mg/m
3) . . . 250 500 250 500
CMD (nm) 154 189 313 338
σ g 1.60 1.56 1.60 1.62
MMD (nm) 300 373 678 756
Lung-deposited particle fraction* 0.11 0.11 0.05 0.05
Lung-deposited particle dose per h (μg/h)** 49.5 99 22.5 45
about 1.60 for all cases (Table 2). Multiplication of each size
bin of the number size distribution with the respective (spher-
ical) particle volume (πd3/6, d= particle diameter) and density
(1 g/cm3) provided the corresponding mass-weighted size distri-
bution. As depicted in Figure 1(B), the mass-weighted size dis-
tribution showed an MMD (mass median diameter) of 300 and
678 nm for sidestream and mainstream CS particles respectively,
confirming that mainstream CS particles were approximately two
times larger than sidestream CS particles. The increased size of
mainstream particles was observed for both concentration set-
tings (250 and 500 mg/m3), with 10–20 % larger diameters for the
500 mg/m3 case (Table 2). It is important to note that even though
a significant fraction of the mass-based mainstream size distribu-
tion was beyond the upper sizing limit of the SMPS (1000 nm),
the reported MMD were still reliable, since the curve fit was per-
formed simultaneously on all moments (number, length, surface
area and mass) as described in the Materials and methods section.
From the size distribution parameters provided in Table 2, the
biologically relevant lung deposited dose was calculated by mul-
tiplying the aerosol mass concentration by the inhaled air volume
(1.8 l/h) and the lung-deposited particle fraction (at the MMD)
provided by Nadithe et al. [31]. The lung deposited particle dose
ranged from 22.5 to 99 μg/h, depending on the aerosol mass
concentration and sidestream or mainstream smoke conditions.
Although there are several in silico models of particle deposition
in the lungs of mice, their general trend predicted elevated de-
position of 300 nm relative to 700 nm particles, due to enhanced
diffusional deposition of 300 nm particles [31].
In summary, mainstream CS particles were approximately two
times larger than sidestream CS particles for a given TPM level.
Enhancing the TPM level from 250 to 500 mg/m3 increased the
particle size only moderately (10–20 %). This indicates that the
type of CS generation (mainstream/sidestream) was more relev-
ant for the observed particle size than the TPM level. Interest-
ingly, the biologically relevant, i.e. lung deposited particle dose
for 250 mg/m3 TPM sidestream conditions corresponded closely
to the pulmonary dose delivered for 500 mg/m3 TPM mainstream
conditions (Table 2).
Organic composition of CS particles
A total of 14 relevant PAHs in the PM CS were analysed (Table 3).
Sidestream CS showed extremely high concentrations of PAH.
The most toxic Benz[a]pyrene [LD50 (rat) = 50 mg/kg] within the
compound class of PAHs were found in potentially harmful con-
centrations in sidestream CS (1.4 μg/m3 at 250 mg/m3 TPM and
2.7 μg/m3 at 500 mg/m3 TPM, with corresponding lung delivered
doses of 0.069 and 0.13 μg/kg respectively), whereas the levels
below the LOQ (limit of quantification; 1 ng/m3) were measured
in mainstream CS. The composition of mainstream CS showed
no significant differences in concentrations of PAHs with regards
to different TPM levels.
The n-alkanes and the branched alkanes (Table 4) showed
the typical pattern of CS as already described [32]. Alkanes
with odd carbon numbers are mainly formed, in particular with
C-numbers C27–C33. For branched alkanes, an alternation can
be observed between odd-C-numbered iso-alkanes and even-C-
numbered anteiso-alkanes. The most abundant iso-alkanes were
isononacosane (i-C29), isohentriacontane (i-C31) and isotritriac-
ontane (i-C33), whereas the most abundant anteiso-alkanes were
anteisotriacontane (a-C30) and anteisodotriacontane (a-C32). In
contrast with the PAHs, significantly higher amounts of alkanes
in sidestream CS were only found at 500 mg/m3 TPM.
CC in the gas phase of CS
A total of 12 relevant CCs were identified in gas phase
emissions from CS. Among those, acetaldehyde dominated in
both sidestream and mainstream CS emissions with 250 and
500 mg/m3 TPM (Table 5). This predominance of acetaldehyde
was already described in previous studies [33,34]. Unsaturated
CCs such as acrolein, methacrolein and crotonaldehyde were also
found in relevant concentrations in both types of CS.
For most of the identified CCs the concentrations in sidestream
CS were generally higher compared with mainstream CS and
also showed greater than 2-fold increases with increasing TPM
concentrations.
BAL inflammation after sidestream CS exposure
lacks neutrophilic influx
To determine inflammatory cell recruitment in BALs, differential
cell counts on May–Gru¨nwald–Giemsa-stained cytospins were
performed.
The 3 days of mainstream CS exposure significantly in-
creased total cell numbers from control levels (44 167+− 9601) to
83 000+− 21 389 for 250 mg/m
3 TPM and 149 750+− 38 756 for
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Table 3 Sidestream and mainstream yields of PAH from two different cigarette smoke concentrations
P values were calculated using Student’s unpaired t test. Values in bold are significant. <DL, below detection limit; na, not
analysed.
Sidestream Mainstream
Substance (µg/m3) 250 mg/m3 500 mg/m3 P value 250 mg/m3 500 mg/m3 P value
Phenanthrene 28.6 55.0 0.01 8.6 8.4 0.7
Anthracene 6.1 14.3 0.01 1.7 1.5 0.5
Pyrene 11.1 18.2 0.02 3.1 2.6 0.1
Fluoranthene 4.7 7.1 0.01 2.5 2.4 0.6
Benzo[a]anthracene 2.2 4.0 0.00 0.5 <DL na
Chrysene 7.7 15.0 0.01 0.9 <DL na
Sum Benzofluoranthenes 2.0 4.1 0.00 <DL <DL na
Benzo[e]pyrene 0.7 1.3 0.35 <DL <DL na
Benzo[a]pyrene 1.4 2.7 0.01 <DL <DL na
Perylene 1.2 2.8 0.11 <DL <DL na
Dibenzo[ah]anthracene <DL <DL na <DL <DL na
Indeno[1,2,3-cd]pyrene 1.3 1.8 0.08 2.6 2.5 0.6
Benzo[ghj]perylene <DL 1.1 na <DL <DL na
Coronene <DL <DL na <DL <DL na
Sum PAH 67.0 126.9 0.00 19.4 17.3 0.1
Table 4 Summary of n-alkanes and iso- and anteiso-alkanes in sidestream and mainstream CS
P values were calculated using Student’s unpaired t test. Values in bold are significant. na, not analysed.
Sidestream Mainstream
Substance (µg/m3) 250 mg/m3 500 mg/m3 P value 250 mg/m3 500 mg/m3 P value
Nonadecane 90.3 97.9 0.52 193.5 60.1 na
Eicosane 82.7 163.5 0.01 43.1 59.3 0.14
Heneicosane 105.1 224.0 0.01 65.0 149.2 0.09
Docosane 111.7 269.5 0.10 75.8 64.1 0.29
Tricosane 86.8 237.6 0.01 73.1 57.5 0.15
Tetracosane 103.9 174.3 0.03 64.3 61.7 0.55
Pentacosane 189.4 379.9 0.01 147.8 117.3 0.00
Heptacosane 1006.2 2181.8 0.00 1040.6 825.1 0.04
Nonacosane 874.0 2170.7 0.00 1084.1 861.9 0.06
Triacontane 259.7 632.9 0.00 326.3 240.9 0.02
Hentriacontane 2966.9 7756.1 0.00 3677.9 2738.7 0.03
Dotriacontane 495.3 1199.4 0.02 695.3 513.9 0.03
Tritriacontane 1358.2 3609.9 0.00 2151.3 1515.5 0.03
Tetratriacontane 70.6 138.5 0.01 118.8 172.3 0.19
Pentatriacontane 41.5 78.7 0.06 57.2 48.5 0.13
Iso-nonacosane 169.4 452.3 0.00 222.7 192.4 0.34
Anteiso-triacontane 686.5 1749.8 0.02 838.4 837.7 1.00
Iso-hentriacontane 1069.2 3194.0 0.00 1578.0 1415.0 0.21
Anteiso-dotriacontane 1510.2 3639.7 0.03 2016.3 1918.0 0.71
Iso-tritriacontane 547.5 1440.8 0.00 735.6 650.8 0.22
500 mg/m3 TPM respectively (Figure 2A). These mice showed
BAL inflammation predominantly consisting of neutrophils and
macrophages that were significantly elevated after exposure to
500 mg/m3 TPM (Figures 2B and 2C). Neutrophil numbers in-
creased from 152+− 203 in filtered air controls to 16 238+− 5878
at 250 mg/m3 TPM and to 45 158+− 29 315 at 500 mg/m
3.
Macrophages increased from 48 967+− 12 636 in filtered air
controls to 69 080+− 18 357 for 250 mg/m
3 TPM and to
103 523+− 33 576 for 500 mg/m
3 TPM.
In contrast, BAL inflammation in the sidestream model
was dominated by macrophages, leading to significantly el-
evated total cell and macrophage numbers after CS ex-
posure to 500 mg/m3 TPM compared with control anim-
als (Figures 2A and 2B). Total cell counts increased from
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Table 5 Carbonyl compounds in the gas phase of sidestream and mainstream CS
P values were calculated using Student’s unpaired t test.
Sidestream Mainstream
Compound (µg/m3) 250 mg/m3 500 mg/m3 P value 250 mg/m3 500 mg/m3 P value
Formaldehyde 207.6 318.7 0.02 477.8 1027.5 0.00
Acetaldehyde 8000.0 11000.0 0.00 11900.0 32300.0 0.00
Propanal 330.5 492.2 0.00 415.4 1229.9 0.00
Acetone 2290.0 3120.0 0.00 2860.0 9700.0 0.00
Acrolein 139.7 263.6 0.00 336.1 746.6 0.01
Methacrolein 108.1 204.5 0.00 243.7 711.3 0.00
Crotonaldehyde 144.0 279.9 0.00 152.0 317.9 0.00
Isobutanal 128.3 228.2 0.00 131.2 318.2 0.00
Butanal 312.0 521.2 0.01 220.4 816.8 0.00
Butan-2-one 629.5 823.0 0.02 329.3 934.3 0.00
Isopentanal 241.1 432.2 0.00 221.5 548.9 0.00
Butan-2,3-dione 310.8 635.4 0.00 312.9 753.9 0.00
Figure 2 Characterization of BAL inflammation after acute smoke exposure reveals lack of neutrophilic influx in
sidestream CS-exposed mice
The lungs of mice exposed to CS for 3 days were lavaged with 4×0.5 ml aliquots of sterile PBS. Total cell counts were
determined in a haemocytometer via Trypan Blue exclusion. Differential cell counts were performed using morphological
criteria on May–Gru¨nwald-Giemsa–stained cytospins (200 cells/sample). (A) Total cell counts. (B) Macrophages. (C)
Neutrophils. (D) Lymphocytes. Results are means+−S.D., one-way ANOVA following Bonferroni post-hoc test. **P<0.01
and ***P<0.001; FA, filter air; n=12. ns, not significant.
41 071+− 23 579 in controls to 83 000+− 26 609 in 250 mg/m
3
TPM and to 123 889+− 66 628 in 500 mg/m
3 TPM respectively.
Macrophage numbers increased from 40 657+− 23 659 in controls
to 81 881+− 25 488 in 250 mg/m
3 TPM and to 123 240+− 66 195 in
500 mg/m3 TPM. BAL neutrophils remained unchanged after ex-
posure to both sidestream CS concentrations (Figure 2C), lead-
ing to a significant difference in neutrophil cell counts between
animals exposed to 500 mg/m3 mainstream CS compared with
500 mg/m3 sidestream CS.
As expected, lymphocyte numbers did not show any increase
in both models compared with filtered air control animals (Fig-
ure 2D), confirming previous findings of two phases of inflam-
matory responses, with elevated lymphocyte levels starting after
1 month of CS exposure [12–14].
In sum, these results demonstrate that: (i) the CS concen-
tration in the exposure chamber determines inflammatory cell
recruitment to the alveolar lumen; and (ii) after sidestream CS
exposure, a neutrophilic influx is not detectable.
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Figure 3 BAL inflammatory cytokine secretion after acute smoke exposure is only increased in mainstream CS-exposed
mice
Concentrations of secreted cytokines KC (A), TNF-α (B), MIP-2 (C), MIP-1α (D) and MCP1 (E) in BAL after 3 days of CS
exposure were determined using a magnetic bead-based multiplex assay. For this assay, BAL fluid was concentrated (10×)
by ultrafiltration in centrifugal filter devices. Results are means+−S.D., one-way ANOVA following Bonferroni post-hoc test.
*P<0.05, **P<0.01 and ***P<0.001; FA, filter air; n=12. ns, not significant.
BAL inflammatory cytokines and chemokines are
only increased after mainstream CS exposure
The secretion of a broad variety of inflammatory cytokines and
chemokines into the airway lumen was analysed by sampling
BAL fluid via a magnetic bead-based multiplex assay.
Significantly up-regulated inflammatory mediators were only
observed in BAL of mice exposed to mainstream CS compared
with filtered air controls (Figure 3). Specifically, KC (CXCL1),
TNF-α, MCP-1 (CCL2), MIP2 (CXCL2) and MIP-1α (CCL3),
all of which are involved in innate immune cell activation and
recruitment, were detected and found to be induced predomin-
antly by the higher CS concentration of 500 mg/m3 TPM. In
the sidestream model, no up-regulation was seen for any of the
cytokines analysed in BAL as well as in the lung tissue homo-
genates (results not shown) of CS-exposed mice, explaining the
significant differences in cell recruitment observed between an-
imals exposed to mainstream CS compared with sidestream CS.
These results indicate a strong acute inflammatory response in
the mainstream CS model, whereas there is no increased cytokine
secretion after sidestream exposure for the markers analysed.
Lung tissue inflammation is more prominent in
mainstream CS-exposed mice
Lung tissue inflammation was further investigated by analys-
ing mRNA expression levels of inflammatory target genes KC
(CXCL1), TNF-α, MIP2 (CXCL2), MMP12 and CD68 in ho-
mogenized lung tissue.
In the mainstream CS model, mRNA levels for KC
(CXCL1), MIP2 (CXCL2) and MMP12 were significantly in-
creased after exposure of mice to CS concentrations of 250
and 500 mg/m3 TPM compared with control animals (Fig-
ures 4A, 4C and 4D). Interestingly, CD68 only showed elevated
mRNA expression after CS exposure to 250 mg/m3 TPM (Fig-
ure 4E), whereas TNF-α did not increase at both concentrations
(Figure 4B).
Mice exposed to sidestream CS also exhibited higher KC
mRNA levels for both CS concentrations compared with con-
trol animals (Figure 4A). In contrast with the mainstream
model, TNF-α showed elevated mRNA expression after CS
exposure to 500 mg/m3 TPM (Figure 4B). However, MIP2
(CXCL2), MMP12 and CD68 did not increase at both con-
centrations (Figures 4C–4E). Significant differences in mRNA
levels between animals exposed to mainstream CS compared with
sidestream CS were observed for KC, MIP2 (CXCL2), MMP12
and CD68, mostly at higher CS concentrations of 500 mg/m3
TPM.
These results demonstrate that the strong acute inflam-
mation observed in BAL (with increases in inflammatory
cell recruitment and cytokine/chemokine secretion) after main-
stream CS exposure was concomitant with increases in mRNA
expression levels of inflammatory marker genes in lung
tissue.
Despite the findings of elevated mRNA expression of several
proinflammatory genes, H&E staining of lung tissue from both
models revealed only marginal inflammatory cell infiltrates after
sidestream exposure to a CS concentration of 500 mg/m3 TPM
(Figure 5). Furthermore, we did not observe any differences in
lung function between control animals and CS-exposed mice
from both exposure models (results not shown).
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Figure 4 Gene expression profile in lung tissue after acute smoke exposure shows more prominent inflammation in
mainstream CS-exposed mice
mRNA expression levels of target genes KC (A), TNF-α (B), MIP-2 (C), MMP12 (D) and CD68 (E) in comparison with
housekeeping control HPRT-1 were determined via quantitative real-time PCR using cDNA synthesized from lung tissue ho-
mogenate. Primers used are listed in Table 1. Relative mRNA expression of a gene is given as 2−Ct (Ct=Cttarget −Ctreference ),
relative changes compared with control are 2−Ct values (Ct =Cttreated −Ctcontrol ). Results are means+−S.D., one-way
ANOVA following Bonferroni post-hoc test. *P<0.05, **P<0.01 and ***P<0.001; n=12. FA, filter air; n=12. ns, not
significant.
Figure 5 HE staining of lung tissue slides from mice exposed to filter air (A and D), sidestream (B and C) and mainstream
(E and F) CS
Exemplary micrographs revealed marginal inflammatory cell infiltrates after sidestream exposure to a CS concentration of
500 mg/m3 TPM (black arrows). Magnification 20×, scale bar 200 μm. FA, filter air.
Sidestream CS exposure leads to higher CO
concentrations in the exposure chamber
CO, a gas derived from partial, i.e. incomplete, oxidation of
carbon-containing compounds, is not only known to have toxic
effects [35], but has revealed an important biological activity as
a signalling molecule with protective actions against apoptosis
and endothelial oxidative damage [36]. Therefore CO concentra-
tions in the exposure chamber were constantly monitored during
smoke exposure using a CO meter.
Mainstream CS of 250 and 500 mg/m3 TPM caused CO
concentrations of 266+− 42 and 288+− 74 ppm, respectively
(Figure 6A). On the other hand, sidestream CS exposure led to
significantly higher CO levels in the exposure chamber compared
with mainstream CS, with 563+− 119 ppm for 250 mg/m
3 TPM
and 1008+− 49 ppm for 500 mg/m
3 TPM.
To determine the effects of CO levels on mice in the exposure
chamber, arterial blood CO-Hb was measured in a subgroup of
mice (n= 4), 30 min after the last exposure. All mice tolerated
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Figure 6 CO concentrations in the exposure chamber, levels of ar-
terial blood CO–Hb and body weight changes in mice after acute
smoke exposure
(A) CO concentrations in the exposure chamber were monitored by using
a GCO 100 CO Meter (n=4 measurements during one exposure cycle).
(B) Levels of arterial blood CO-Hb in a subgroup of mice (n=4) 30 min
after CS exposure were determined by retro-orbital blood sampling
and analysed in an ABL80 FLEX blood gas analyser. (C) Body weight
changes of CS-exposed mice on day of analysis (day 4); n=12. Results
are means+−S.D., one-way ANOVA following Bonferroni post-hoc test.
**P<0.01 and ***P<0.001. FA, filter air; n=12. ns, not significant.
CS-mediated CO concentrations without any sign of toxicity. In
the mainstream model, arterial blood CO-Hb levels in mice ex-
posed to 250 and 500 mg/m3 TPM increased from control values
(0.3+− 0.2 %) in filtered air animals to 13.2+− 1.1 and 12.2+− 2.4 %
respectively (Figure 6B). This is consistent with the similar levels
of CO observed in the exposure chamber for both concentration
levels of mainstream CS. Sidestream CS exposure to 250 mg/m3
TPM showed 15.0+− 1.8 % at similar increases in CO-Hb com-
pared with mainstream CS, in spite of almost 2-fold higher CO
levels. In contrast, sidestream CS of 500 mg/m3 TPM was asso-
ciated with significantly higher CO-Hb levels (27.1+− 2.5 %) in
mice compared with 500 mg/m3 mainstream CS (12.2+− 2.4 %).
During the 3 days of smoke exposure, the body weight of all
animals was monitored. Compared with controls, mice exposed
to either main- or side-stream CS did not show any significant
body weight changes during the whole exposure period (results
not shown). However, a significant body weight difference (nor-
malized to weight of each group on day 1) between animals
exposed to 500 mg/m3 TPM of mainstream and sidestream CS
was observed on the day of animal preparation (day 4), 24 h after
the last CS exposure (Figure 6C), at 105.9+− 7.7 % (mainstream)
compared with 93.2+− 8.4 % (sidestream).
These results demonstrate that sidestream CS exposure is
associated with increased CO concentrations in the exposure
chamber, thereby inducing elevated CO-Hb levels and body
weight changes in mice especially for the CS concentration of
500 mg/m3.
GM-CSF is only up-regulated in BAL and lung tissue
of mainstream CS-exposed mice
Previous studies have described a role for GM-CSF in CS-
induced pulmonary inflammation [37], and decreased GM-
CSF production following CO exposure was observed in LPS
(lipopolysaccharide)-stimulated macrophages [38]. Therefore
mRNA and protein levels of GM-CSF in lung tissue and BALs
were determined in the present study.
mRNA expression levels of GM-CSF did not increase in
sidestream CS-exposed mice, whereas the mainstream model
shows a significant up-regulation for both CS concentrations
(Figure 7A). The same was observed for secreted GM-CSF ana-
lysed in BAL of CS-exposed mice (Figure 7B), confirming the
important role for GM-CSF in inflammatory cell recruitment in
response to CS and its potential inhibition by CO.
DISCUSSION
The present study aimed at investigating the composition of CS
and the acute inflammatory response in the lungs of mice using
two different experimental models of CS exposure for 3 days.
The results presented here demonstrate that the composition of
CS (TPM and CO concentration, chemical composition and size
distribution of PM) determines the dynamics of inflammatory
cell recruitment to the mouse lung.
CS is a toxic collection of more than 4800 chemicals and
exceptionally rich in oxidants both in the gaseous and particle
phases [39,40]. It is the major risk factor for cardiovascular
diseases, atherosclerosis and lung diseases such as COPD and
cancer. COPD is a disease characterized by airflow limitation
caused by severe pathophysiological changes including chronic
bronchitis, small airway remodelling, mucus production and the
development of emphysaema [2]. In order to recapitulate these
changes observed in patients suffering from COPD, CS-induced
animal models are commonly used in laboratories around the
world. Acute CS exposure has enabled researchers to study early
and direct effects of smoking on inflammatory responses and cell
recruitment, specifically innate immune cells and oxidative stress
in the lung [20–22,24].
It is now generally accepted that the inflammatory response
plays a major role in driving the pathophysiological changes
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Figure 7 GM-CSF expression and secretion after acute smoke ex-
posure is only up-regulated in lung tissue and BAL of mainstream
CS-exposed mice
(A) mRNA expression levels of GM-CSF in comparison with house-
keeping control HPRT-1 were determined via quantitative real-time
PCR using cDNA synthesized from lung tissue homogenate. Primers
used are listed in Table 1. Relative mRNA expression is given as
2−Ct (Ct=Cttarget −Ctreference ), relative changes compared with control
are 2−Ct values (Ct =Cttreated −Ctcontrol ). (B) Concentrations of
secreted GM-CSF in BAL after 3 days of CS exposure were determined
using a magnetic bead-based multiplex assay. For this assay, BAL fluid
was concentrated (10×) by ultrafiltration in centrifugal filter devices.
Results are means+−S.D., one-way ANOVA following Bonferroni post-hoc
test. ***P<0.001. FA, filter air; n=12. ns, not significant.
observed in COPD [15,16]. Identical to observations in humans,
CS constantly induces a neutrophil and macrophage inflammat-
ory response in the lower respiratory tract of exposed animals (re-
viewed in [11,41]), and the acute reaction during the first week of
CS exposure is dominated by a strong neutrophilic influx [12–14].
All studies looking at the dynamics of early lung immune
cell reactions to CS used the mainstream model in acute settings
of smoke exposure for a few days. In accordance with these
studies, a strong acute inflammatory response characterized by
neutrophilic influx, increased cytokine secretion (KC, TNF-α,
MIP-2, MIP-1α and MCP1), proinflammatory gene expression
(KC, MIP-2 and MMP12) and up-regulated GM-CSF production
was observed in the mainstream CS model.
In contrast, only one study ever utilized the sidestream model
in an acute setting, but did not focus on lung inflammation [24].
Howard et al. [24] investigated oxidative DNA damage via ana-
lysis of 8-OHdG (8-hydroxy-2′-deoxyguanosine) in mouse heart,
liver and lung tissue and detected increased levels already after
a single CS exposure for 30 min. In a chronic setting, Wood-
ruff et al. [42] did not even observe neutrophil recruitment after
exposures for 1, 2 and 3 months using the sidestream model,
whereas macrophages were increased. Interestingly, the results
of the present study show that there was a dampened inflammat-
ory reaction after sidestream exposure, characterized by macro-
phages and slight increases in TNF-α mRNA expression.
In response to CS, neutrophils and macrophages release cy-
tokines and proteolytic enzymes and generate oxidants, thereby
causing tissue damage and perpetuating inflammation and im-
mune reactions [41]. Gene expression profiling also revealed an
early up-regulation of stress response and inflammation markers
after acute CS exposure [13]. The proteolytic enzymes MMP12
and NE were even required for inducing experimental emphy-
saema after prolonged exposure [17,18]. CS-exposed MMP12-
knockout mice failed to recruit macrophages and did not develop
lung destruction [17], whereas NE was necessary for neutrophil
and monocyte recruitment as well as for the activation of MMP12
after CS exposure [18].
Several studies characterized the inflammatory response after
gradually increasing the exposure time and dose in the acute
mainstream model [20–22]. Stevenson et al. [20] described a
time- and dose-dependent increase in neutrophil chemokines,
specifically CXCR2 ligands in the rat lung, which was mirrored
by neutrophil infiltration. The work by Vlahos et al. [21] detected
mRNA up-regulation of chemokines such as MIP-2 and MCP1,
inflammatory mediators such as TNF-α, the leucocyte growth and
survival factor GM-CSF and matrix degrading MMPs 9 and 12.
Morris et al [22] confirmed time- and dose-dependent neutrophil
increases in four different mouse strains, with highly up-regulated
KC and MMP12 levels. The results of the present study also
showed an mRNA up-regulation of CXCR2 ligands KC and MIP-
2 as well as MMP12 after mainstream CS exposure. An increase
in cytokine secretion was observed for KC, TNF-α, MIP-2, MIP-
1α and MCP1.
The differences seen between sidestream and mainstream CS
could be related to the biologically relevant, i.e. lung deposited
PM dose. The observed smaller particle size in sidestream relat-
ive to mainstream CS was translated into a difference in the lung
deposited dose using in silico models for particle deposition in the
murine lung [31]. For a given TPM level, the lung-delivered PM
dose of sidestream CS was approximately two times higher than
for mainstream CS (see Table 2). Despite the enhanced biologic-
ally effective dose for sidestream CS conditions, the biological
response for a given TPM level was less pronounced compared
with the mainstream model. Thus, the pulmonary dose of PM
cannot account for the inhibited inflammatory response in the
sidestream CS model.
Besides the lung-delivered dose, the chemical composition
of CS might influence the observed biological reactions. Main-
stream and sidestream CS exhibit differences in the chemical
profile, which is particularly related to the different combustion
conditions during puffing and smoldering. Therefore the toxico-
logical impact of mainstream and sidestream CS most probably
differs as well. Sidestream CS is formed under more oxygen-
deficient conditions at lower temperatures compared with main-
stream CS. Large differences are obtained for the yields of toxic
gaseous compounds such as acrolein, butadiene or benzene and
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CO, which are much higher for sidestream CS [43,44]. In ad-
dition, sidestream CS is characterized by significantly higher
relative concentrations of nitrogen-containing compounds (e.g.
ammonia or aniline- and pyridine-derivatives) [44], whereas
mainstream CS exhibits higher concentrations of nitric oxide.
In the present study, CS-associated PAHs and alkanes were
analysed. PAHs are a product of incomplete combustion as well
as pyrolysis processes. Humans are mainly exposed to PAHs
via inhalation of aerosols, such as CS particles. Animal test-
ing has shown that many PAHs are potentially carcinogenic as
PAH molecules bind to the AH (aromatic hydrocarbon) recept-
ors. The enzymatic degradation yields in phenols and epoxides
are caused by cytochrome P-450 dependent oxidases. The epoxy
metabolites are partially transferred to dihydrodiol epoxides be-
fore excretion. Owing to ring-opening reactions, these epoxy
derivatives can bind to DNA bases [45]. The knowledge of acute
toxicity is sparse, but chronic health effects are to be expected,
including lung, immune and reproduction toxicity. Furthermore,
the total amount of alkanes far beyond 1 mg/m3 can cause irrit-
ations of the respiratory tract. The concentrations of n-alkanes
and iso- and anteiso-alkanes in the 500 mg/m3 sidestream CS
samples (0.75–8.53 ng/m3) were higher than those measured in
250 mg/m3 sidestream CS samples (0.77–1.51 ng/m3). There-
fore differences in PM composition depending on the TPM
level are expected. However, alkane as well as PAH concen-
trations only increased with higher TPM levels of sidestream
CS, indicating the typically lower combustion temperatures
and subsequently less complete combustion in sidestream CS
conditions [44].
Sidestream CS of 250 mg/m3 and 500 mg/m3 TPM con-
tained 3.4-fold and 7.2-fold higher PAH levels than mainstream
CS respectively. The observed high concentrations of PAHs in
sidestream CS indicate that high amounts of PAHs are formed
during the smoldering phase of cigarette smoking when no puff is
made [44]. In contrast with sidestream CS, the availability of oxy-
gen and high temperatures during a puff of mainstream CS results
in a more complete combustion of organic compounds yielding
lower concentrations of PAHs. These results show the import-
ance of sidestream CS for public health implications. However,
the higher concentrations of PAHs and alkanes in sidestream CS
were not reflected in enhanced biological responses in our model,
suggesting a significant role of gas-phase components especially
for sidestream CS.
CCs are important gaseous constituents of CS and some
are toxic and carcinogenic or mutagenic to humans. They are
highly reactive towards nucleophilic molecules in the cell such
as DNA, proteins, aminophospholipids and glutathione and
thereby contribute to the development of smoking related dis-
eases [46,47]. The findings of the present study are in line with
previous observations that higher concentrations for CCs such as
acetaldehyde, acrolein, methacrolein and crotonaldehyde in the
sidestream model might be caused by the incomplete combustion
of sidestream CS as already described above.
Acrolein was described as effective in eliciting IL-8 release
in pulmonary cells thereby contributing to neutrophil chemotaxis
and activation [48,49]. Despite the higher production of acrolein
in sidestream CS, we did not detect any appreciable level of neut-
rophils. Notably, this unresponsiveness needs further analysis.
However, the dampened inflammatory response observed in the
sidestream model might be related to elevated CO concentrations
in the exposure chamber resulting in significantly higher levels
of arterial blood CO-Hb in CS-exposed mice at 500 mg/m3 TPM
compared with mainstream CS. Recent reviews pointed out the
anti-inflammatory effects of CO in a multitude of in vitro studies
and animal models of inflammation, indicating a therapeutic po-
tential [36,50]. Besides its known toxic effects, CO has revealed
an important biological function by protecting against apoptosis
and endothelial oxidative damage. Recently, CO was shown to
mediate anti-apoptotic effects of HO (haem oxygenase)-1, an iso-
form of the enzyme HO involved in the oxidative degradation of
haem [51]. Moreover, CO as one of the three main byproducts
of the catabolism of haem by HO altered iron homoeostasis in
the lung thereby reducing oxidative stress and proliferation of
bronchial epithelial cells [52].
An important study recently showed a protective effect of in-
haled CO during pulmonary inflammation after LPS challenge
[53]. CO administered to mice both before and after intratracheal
instillation of LPS was effective in reducing neutrophil recruit-
ment to the lung due to decreased bone marrow mobilization of
leucocytes. The authors speculated that the effect on neutrophil
mobilization occurred via decreased production of GM-CSF fol-
lowing CO exposure. This mechanism was already described in
LPS-stimulated murine macrophages [38]. HO-1 overexpression
as well as CO exposure inhibited LPS-induced GM-CSF produc-
tion in macrophages via NF-κB (nuclear factor κB) inhibition,
with NF-κB as the transcriptional regulator of GM-CSF.
As shown in Figure 7 GM-CSF levels for the sidestream CS
model are significantly lower than for the mainstream model.
GM-CSF might have an important role in CS-related lung dis-
eases because it functions as a leucocyte growth, activation and
survival factor [54]. It promotes proliferation and differentiation
of haematopoietic progenitors into neutrophils and macrophages
and is produced by many structural and inflammatory cells.
Furthermore, GM-CSF acts as a direct neutrophil chemotactic
factor and may increase neutrophil survival in the respiratory
tract [55,56]. Vlahos et al. [37] demonstrated that neutralizing
GM-CSF inhibited CS-induced lung inflammation by reducing
BAL neutrophils and macrophages as well as TNF-α, MIP-2 and
MMP12 mRNA expression. Possible mechanisms in this context
were increased apoptosis of neutrophils and macrophages, be-
cause it was already shown that GM-CSF inhibits neutrophil ap-
optosis [57]. Furthermore, the effects of anti-GM-CSF treatment
on MIP-2, another potent neutrophil chemotactic factor, could
also account for the inhibited inflammation. The contribution of
CXCR2-mediated signalling to CS-induced lung inflammation
characterized by neutrophil influx was determined by treatment
of mice with an inhibitor of CXCR2 [58]. A further study block-
ing GM-CSF receptor also described attenuated neutrophil influx
in CS-exposed mice [59], confirming the major role of GM-CSF
in CS-induced pulmonary inflammation.
Thus, the results of the present study are consistent with
the hypothesis that in the sidestream CS model, high levels of
CO and subsequently higher levels of arterial blood CO-Hb led
to inhibited production and release of GM-CSF and CXCR2
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ligands KC and MIP-2. However, despite the lack of difference
in CO-Hb at 250 mg/m3 between the two models a largely differ-
ent inflammatory response was observed. This might also point to
effects of other gas phase components aside from CO that could
significantly alter the inflammatory response in the lung. How-
ever, despite the findings of a dampened inflammatory response,
it must be noted that inhaled fresh sidestream CS is approxim-
ately four times more toxic per gram TPM than mainstream CS
[23]. In animals exposed to whole sidestream CS, sensory ir-
ritation and respiratory tract epithelium damage increases with
longer exposures. However, the results of the present study show
that the enhanced toxicity of TPM from sidestream CS was rather
repressed by the gas-phase effects.
In summary, we demonstrated that significant differences exist
between two mouse models of acute smoke exposure. Mainstream
CS induced a strong acute inflammatory response and led to in-
creased levels of neutrophils and related proinflammatory mark-
ers. In contrast, sidestream CS exposure only caused a dampened
inflammatory reaction, with slightly elevated macrophage num-
bers. The different responses between the two models were most
probably related to elevated CO concentrations, which inhibited
early inflammatory responses in the sidestream CS model. The
COPD mouse models for acute mainstream and sidestream CS
exposure (i.e. also environmental CS) described in the present
study are potentially interesting for evaluating the toxicological
and health effects of other aerosol sources, such as emissions
from house heating (e.g. wood stoves) or traffic-sources (e.g.
trucks, cars or ships).
We conclude that a detailed analysis of physico-chemical and
biological data generated from acute CS models can provide
important information for potential therapeutic interventions at
early stages of smoke exposure.
CLINICAL PERSPECTIVES
 Initial inflammatory processes might contribute to COPD
pathogenesis at an early stage of smoke exposure, but different
animal CS exposure systems have been established and em-
ployed in acute and chronic COPD studies. In order to elucid-
ate potential differences between mainstream and sidestream
CS exposure, we investigated the CS composition and the
acute inflammatory response in the lungs of mice after 3 days
of CS exposure.
 We observed a strong acute inflammatory response character-
ized by neutrophilic influx, increased cytokine secretion and
proinflammatory gene expression, and up-regulated GM-CSF
production in the mainstream CS model, whereas there was
a dampened inflammatory reaction after sidestream exposure,
most probably caused by elevated CO concentrations.
 This comparison might be useful for the interpretation of data
from the various CS mouse models and will potentially impact
on therapeutic intervention studies starting at the early stages
of smoke exposure.
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Chronic obstructive pulmonary disease (COPD) is characterized by a
progressive decline in lung function, caused by exposure to exogenous
particles, mainly cigarette smoke (CS). COPD is initiated and perpet-
uated by an abnormal CS-induced inflammatory response of the lungs,
involving both innate and adaptive immunity. Specifically, B cells
organized in iBALT structures and macrophages accumulate in the
lungs and contribute to CS-induced emphysema, but the mechanisms
thereof remain unclear. Here, we demonstrate that B cell-deficient
mice are significantly protected against CS-induced emphysema.
Chronic CS exposure led to an increased size and number of iBALT
structures, and increased lung compliance and mean linear chord
length in wild-type (WT) but not in B cell-deficient mice. The
increased accumulation of lung resident macrophages around iBALT
and in emphysematous alveolar areas in CS-exposed WT mice coin-
cided with upregulated MMP12 expression. In vitro coculture exper-
iments using B cells and macrophages demonstrated that B cell-
derived IL-10 drives macrophage activation and MMP12 upregula-
tion, which could be inhibited by an anti-IL-10 antibody. In summary,
B cell function in iBALT formation seems necessary for macrophage
activation and tissue destruction in CS-induced emphysema and
possibly provides a new target for therapeutic intervention in COPD.
COPD; B cells; iBALT; IL-10; macrophages
CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) is a major
public health problem and its prevalence as well as morbidity
and mortality are still rising worldwide (50, 53). The stimulus
of long-term exposure to toxic gases and particles, most often
cigarette smoke (CS), induces mucus production, remodeling
of small airways, septal tissue damage, and chronic bronchitis
(36). These severe pathophysiological changes are the cause
for the constant and accelerated decline in lung function
observed in patients suffering from COPD. Currently, there is
no therapy for COPD and treatment can only aim at alleviating
symptoms.
In the lung, chronic CS exposure causes activation and
influx of various inflammatory cells, including both innate
immune cells, with macrophages and neutrophils predominat-
ing, and adaptive immune cells, specifically T and B lympho-
cytes (2, 20). Their numbers are increased in both airways and
parenchyma of patients with COPD (4, 44, 45). Moreover, the
progression and severity of COPD are associated with increas-
ing infiltration of the airways by innate and adaptive immune
cells, which form ectopic lymphoid follicles (LFs) consisting
of B cells surrounded mainly by CD4 T cells (21). Further
studies have confirmed that increased B cell numbers are
observed in the mucosa of large airways in COPD patients
compared with controls (16) and the number of B cell
follicles present in the lung also increases with disease
severity (52).
Highly organized ectopic LFs are referred to as tertiary
lymphoid organs (TLOs) because of their structural similarity
to secondary lymphoid organs, which include distinct B and T
cell areas, germinal centers, and high endothelial venules (1,
10, 33). TLOs form in various tissues targeted by chronic
inflammation and have an important role in maintaining im-
mune responses that can either be harmful or beneficial. They
have been associated with local pathogenic autoantibody pro-
duction (37, 42) or, in respiratory infections and lung cancer,
with favorable outcome (14, 17, 34). However, it is still under
critical debate whether TLOs in COPD are beneficial or harm-
ful because their role in COPD pathogenesis remains unknown
(8, 57).
Lung TLOs, preferentially termed inducible bronchus-asso-
ciated lymphoid tissue (iBALT), have also been described in in
vivo models of COPD. Mice develop LFs after chronic CS
exposure (12, 52). Recently, Litsiou et al. (29) discovered that
CXCL13 is involved in lymphoid neogenesis in COPD by
promoting B cell migration to ectopic sites of lymphoid tissue
formation and by upregulating lymphotoxin on B cells, which
in turn further induces CXCL13 required for follicle expan-
sion. In CS-exposed mice, administration of an anti-CXCL13
antibody prevents the formation of pulmonary LFs, thereby
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attenuating the destruction of alveolar walls and bronchoalveo-
lar lavage (BAL) inflammation (6).
Aside from their involvement in lymphoid neogenesis and
their antibody-producing capacity, B cells can also function as
antigen-presenting cells and provide costimulatory signals to T
cells (15). Furthermore, the secretion of a variety of cytokines
including IL-6 and IL-10 may enable B cells to influence and
modulate differentiation and polarization of macrophages, T
cells, and dendritic cells during the development of the im-
mune response, thereby regulating immune reactions (23). B
cell-mediated modulation of macrophage effector functions via
cytokine secretion has been described to be important for the
outcome of various models of infection, inflammation, and
cancer (3, 32, 56).
In COPD, the role of innate immune cells in CS-induced
lung inflammation and subsequent emphysema development
has been addressed in several animal studies (5, 12). Macro-
phage-derived matrix metalloproteinase (MMP) 12 was de-
scribed as being required for the induction of experimental
emphysema after prolonged CS exposure because CS-exposed
MMP12 knockout mice failed to recruit macrophages and did
not develop lung destruction (7, 18). This finding points to a
primary role for macrophages and derived factors in the de-
velopment of emphysema both in patients and CS-exposed
animals. We hypothesized that B cell-dependent iBALT for-
mation is involved in macrophage activation and polarization,
thereby inducing and maintaining a severe inflammatory re-
sponse that drives the pathophysiological changes in COPD.
Therefore, we monitored the development of COPD in wild-
type (WT) and B cell-deficient knockout mice exposed to CS.
We characterized structural and functional changes, iBALT
formation, and the inflammatory response occurring in lung
tissue. Interestingly, we identified B cell-derived IL-10 as one
of the possible key regulators of MMP12 production in mac-
rophages. Thus the responsiveness of B cells to CS induces
iBALT formation in the lung, thereby leading to accumulation
and activation of matrix-degrading macrophages. This finding
could lead to the development of new therapeutic targets for
the treatment of COPD patients.
MATERIALS AND METHODS
Animals and maintenance. B cell-deficient B6.129S2-Igh-6tm1Cgn
mice (27), also known as MT mice, and their respective 8- to
10-wk-old pathogen-free female C57BL/6 WT control mice were
purchased from Charles River (Sulzfeld, Germany). Animals were
housed in rooms maintained at constant temperature and humidity
with a 12-h light cycle and were allowed food and water ad libitum.
All experiments were conducted under strict governmental and inter-
national guidelines and were approved by the local government for the
administrative region of Upper Bavaria.
Cigarette smoke exposure. CS was generated from 3R4F Research
Cigarettes (Tobacco Research Institute, University of Kentucky, Lex-
ington, KY). Mice were whole body exposed to 100% mainstream CS
of 500 mg/m3 total particulate matter (TPM) for 50 min twice per day
for 1, 4, and 6 mo in a manner mimicking natural human smoking
habits (24). Control mice were kept in a filtered air (FA) environment,
but exposed to the same stress as CS-exposed animals. At 24 h after
the last CS exposure, mice were euthanized.
The TPM level was monitored via gravimetric analysis of quartz
fiber filters prior and after sampling air from the exposure chamber
and measuring the total air volume. CO concentrations in the exposure
chamber were constantly monitored by using a GCO 100 CO Meter
(Greisinger Electronic, Regenstauf, Germany) and reached values of
288  74 ppm. All mice tolerated CS-mediated CO concentrations
without any sign of toxicity, with CO-Hb levels of 12.2  2.4%.
Experiments were performed with n  8 animals per group and were
repeated twice. All animals were subjected to lung function analysis.
Afterward, n  4 animals per group were lavaged, the right lung was
shock-frozen in liquid nitrogen, and the left lung was fixed in
paraformaldehyde (PFA; see below). The remaining n  4 animals
per group were used for FACS analysis of whole lung single-cell
suspensions.
Elastase application. Emphysema was induced in mice by oropha-
ryngeal application of porcine pancreatic elastase (PPE, 80 U/kg body
wt in 80 l volume) as previously described (59). Control mice
received 80 l of sterile PBS. Mice were killed on day 28. Experi-
ments were performed with n  8 animals per group and were
repeated twice.
Lung function measurement. Pulmonary function in mice was
measured by use of a flexiVent system (Scireq, Montréal, Canada).
Mice were anesthetized with ketamine-xylazine, tracheostomized, and
connected to the flexiVent system. Mice were ventilated with a tidal
volume of 10 ml/kg at a frequency of 150 breaths/min to reach a mean
lung volume similar to that of spontaneous breathing. Testing of lung
mechanical properties including dynamic lung compliance and resis-
tance was carried out by a software-generated script. Measurements
were repeated four times per animal.
Preparation of BAL. BAL was obtained to perform total and
differential cell counts for inflammatory cell recruitment of neutro-
phils, macrophages, and lymphocytes. The lungs were lavaged by
instilling the lungs with 4  0.5 ml aliquots of sterile PBS (GIBCO,
Life Technologies, Darmstadt, Germany). For cytospins, cells were
spun down at 400 g and resuspended in RPMI-1640 medium contain-
ing 10% FCS (both from GIBCO). Total cell counts were determined
in a hemocytometer. Differential cell counts were performed by using
morphological criteria on May-Grünwald-Giemsa-stained cytospins
(200 cells/sample). BAL fluid was used to evaluate cytokine secretion
via multiplex analysis.
Lung tissue processing. Lung tissue was either shock-frozen in
liquid nitrogen to isolate mRNA for gene expression analysis or fixed
at a constant pressure (20 cm fluid column) by intratracheal instilla-
tion of PBS buffered 6% PFA and embedded into paraffin for
histological analysis of hematoxylin-eosin (HE)-stained slides and for
immunohistochemistry.
For analysis of lymphocyte infiltration, single-cell suspensions of
whole lung tissue were used. Lungs were perfused with sterile PBS
via the right ventricle to clear leukocytes and erythrocytes from the
pulmonary circulation. Lung homogenization was performed via en-
zymatic digestion and mechanical dissociation steps using a lung
dissociation buffer and the gentleMACS Dissociator (both from
Miltenyi Biotec, Bergisch Gladbach, Germany). After dissociation,
samples were applied to a filter to remove any remaining larger
particles from the single-cell suspensions.
FACS analysis of whole lung lymphocyte infiltration. For FACS
analysis of single-cell suspensions, one part of the sample was directly
labeled with FACS antibodies against T and B cell surface antigens.
Staining of activated T lymphocytes was performed with antibodies
against CD4, CD8 (both from eBioscience, San Diego, CA), and B
lymphocytes were stained with an antibody against CD20 (eBiosci-
ence). Remaining lung cells were subjected to density gradient cen-
trifugation using Pancoll (PAN Biotech, Aidenbach, Germany) to
isolate mononuclear cells. Isolated cells were cultured overnight in
anti-CD3/anti-CD28-coated plates to perform intracellular cytokine
staining. On the following day, cultivated cells were restimulated with
leukocyte activation cocktail with Golgi Plug (BD Pharmingen) for 4
h. Afterward, cells were stained with anti-CD4, fixed in 2% formal-
dehyde, permeabilized in 0.3% saponin buffer, and stained with
antibodies against IL-17A, IFN- (both from eBioscience), and IL-4
(Biozol) to distinguish between different T helper cell subpopulations.
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Multicolor analysis of stained cells was conducted with a BD
FACSCanto II flow cytometer (BD Biosciences, Heidelberg, Ger-
many) and BD FACSDiva software.
Quantitative morphometry. Design-based stereology was used to
analyze sections via an Olympus BX51 light microscope equipped
with a computer-assisted stereological toolbox (newCAST, Visiop-
harm, Hoersholm, Denmark) on HE-stained lung tissue slides as
previously described (59). Air space enlargement was assessed by
quantifying mean linear chord length (MLI) on 30 fields of view per
lung. Briefly, a line grid was superimposed on lung section images.
Intercepts of lines with alveolar septa and points hitting air space were
counted to calculate MLI by applying the formula MLI  Pair 
L(p)/Isepta  0.5. Pair are the points of the grid hitting air spaces,
L(p) is the line length per point, and Isepta is the sum of intercepts of
alveolar septa with grid lines.
Volume of iBALT normalized to the basal membrane was quanti-
fied on 50 fields of view per lung by counting points hitting iBALT
(PiBALT) and intercepts of lines with vessels and airways
(Iairwayvessel). The volume was calculated by applying the formula
V/S  PiBALT.  L(p)/Iairwayvessel.
The frequency of macrophages expressing MMP12 in lung tissue
was quantified on 30 fields of view per lung. A frame grid was
superimposed on lung section images. Within the frame, macrophages
either positive or negative for MMP12 staining were counted and the
percentage of MMP12-positive macrophages was calculated.
Immunohistochemistry. For immunohistochemistry, lungs were
fixed in paraformaldehyde and embedded into paraffin. After depar-
affinizing in xylene and rehydrating in alcohol, the tissue was treated
with 1.8% (vol/vol) H2O2 solution (Sigma-Aldrich, St. Louis, MO) to
block endogenous peroxidase. Heat-induced epitope retrieval was
performed in HIER citrate buffer (pH 6.0, Zytomed Systems) in a
Decloaking chamber (Biocare Medical, Concord, CA). To inhibit
nonspecific binding of antibodies, tissue slides were treated with a
rodent blocking antibody (Biocare Medical). After overnight incuba-
tion with primary antibodies against MMP12 (Abcam, Cambridge,
UK), CD45R (BD Pharmingen), CD3 (Sigma Aldrich), or IL-10
(Santa Cruz Biotechnology, Dallas, TX), tissue slides were incubated
with an alkaline phosphatase-labeled secondary antibody (Biocare
Medical). Signals were amplified by adding chromogen substrate
Vulcan fast red (Biocare Medical). Slides were counterstained with
hematoxylin (Sigma-Aldrich) and dehydrated in xylene. Afterward,
coverslips were mounted.
Quantitative real-time RT-PCR. Total RNA from lung tissue ho-
mogenate was isolated by using a peqGOLD Total RNA Kit (Peqlab,
Erlangen, Germany) according to the manufacturer’s instructions.
cDNA was synthesized by using Random Hexamers and MuLV
Reverse Transcriptase (Applied Biosystems, Darmstadt, Germany).
mRNA expression of target genes KC (CXCL1), TNF-, MCP1,
MMP12, TIMP1, F4/80, IL-17A, CXCL13, IL-10, IL-6, and GM-CSF
compared with housekeeping control hypoxanthine-guanine phospho-
ribosyltransferase (HPRT)-1 was determined by using Platinum
SYBR Green qPCR SuperMix (Applied Biosystems) on a StepOne-
Plus 96-well Real-Time PCR System (Applied Biosystems, Carlsbad,
CA). Relative transcript expression of a gene is given as 2	
Ct
(
Ct  Cttarget 	 Ctreference); relative changes compared with control
are 2	

Ct values (

Ct  
Cttreated 	 
Ctcontrol). Primers were
generated by use of Primer-BLAST software (58) and according to
published mRNA sequences.
Western blot. Protein (20 g) was separated by SDS-PAGE,
transferred onto a polyvinylidene difluoride membrane (Bio-Rad,
Munich, Germany), blocked by 5% nonfat milk, and immunoblotted
with anti-MMP12 (Millipore, Schwalbach, Germany) antibody. Upon
developing with Amersham ECL Prime reagent (GE Healthcare,
Freiburg, Germany), the bands were detected and quantified by use of
the Chemidoc XRS system (Bio-Rad).
Multiplex cytokine analysis. Concentrations of secreted cytokines
and chemokines KC (CXCL1), TNF-, and MCP1 in BAL were
determined by a magnetic bead-based MILLIPLEX MAG multiplex
assay (Millipore, Schwalbach, Germany) and analyzed on a Lu-
minex100 (Bio-Rad). For this assay, BAL fluid was concentrated
(10) by ultrafiltration in Amicon Ultra-0.5 centrifugal filter devices
(Millipore).
In vitro cell culture experiments. In vitro experiments were per-
formed with the B cell lymphoma line A20 and the macrophage cell
line MH-S, both maintained at 37°C in 5% CO2 atmosphere. A20 cells
were cultured in RPMI-1640 supplemented with 10% FCS, 0.1 mM
2-mercaptoethanol, 100 U/ml penicillin-streptomycin, 10 mM
HEPES, 2 mM L-glutamine, 1 mM sodium-pyruvate, 0.1 mM nones-
sential amino acids, and 1  MEM vitamin solution. MH-S cells were
maintained in RPMI-1640 supplemented with 10% FCS and 0.05 mM
2-mercaptoethanol.
CS extract for stimulation of cells was prepared by bubbling smoke
from three research cigarettes (3R4F; see above) through 30 ml of
RPMI-1640 cell culture medium at puffing speed in a closed envi-
ronment with limited air flow. This stock was considered as 100% CS
extract.
For testing the influence of B cell secreted cytokines on macro-
phages, A20 cells were stimulated either with LPS or with CS extract
for 24 h, and afterward supernatants were used for stimulation of
MH-S cells. In brief, A20 cells were seeded at a density of 4  105
cells per well in a 24-well plate. The following day, A20 cells were
stimulated either with LPS (20 g/ml) as positive control or with CS
extract (1%) and (4%) for 24 h. Pure cell culture medium served as
negative control. After 24 h, supernatants from A20 cells were
removed, centrifuged, and used for stimulation of MH-S cells that had
been seeded the day before at a density of 2  105 cells per well in
a 24-well plate. Stimulation was performed for 6 h; afterward, cells
were lysed for subsequent RNA isolation. Blockade of IL-10 signaling
was performed by adding a blocking anti-IL-10 antibody (Santa Cruz
Biotechnology) to the supernatants 30 min before stimulation of
MH-S cells. All treatments did not significantly affect cell viability
(data not shown).
Determination of IL-10 secretion by ELISA. Concentrations of
IL-10 in the cell culture supernatants were determined by a commer-
cially available kit for enzyme-linked immunosorbent assay (eBiosci-
ence) and normalized to the protein concentration of the lysed cells (as
measured by BCA Protein Assay).
Th17 cell differentiation. Naive CD4 T cells were purified from
total murine splenocytes by use of the CD4CD62L T cell Isolation
Kit II (Miltenyi Biotec). These were then stimulated for 72 h with
anti-CD3/anti-CD28 coupled beads (Life Technologies, Darmstadt,
Germany), along with recombinant human TGF- (10 ng/ml, R&D
Systems, Wiesbaden, Germany), IL-6 (60 ng/ml, R&D Systems),
anti-IL-4 (10 ng/ml, BioLegend, San Diego, CA), anti-IL-12 (10
ng/ml, BioLegend), anti-IFN- (5 ng/ml, BioLegend) and anti-IL-2
(2.5 ng/ml, Miltenyi Biotec). Th0 control cells were stimulated with
anti-CD3/anti-CD28 coupled beads alone for 72 h.
Cells were restimulated with PMA (20 nM) and Ionomycin (1 M,
both from Merck, Darmstadt, Germany) for 5 h with the addition of
brefeldin A (10 g/ml, Sigma-Aldrich) for the last 2.5 h. Cells were
stained with anti-mouse CD4 and Fixable Viability Dye eFluor 450
(both from eBioscience) before fixation with 4% PFA and permeabiliza-
tion in PBS/0.5% saponin/1% BSA. Cells were then stained with anti-
IL-17A (eBioscience) before being analyzed on a BD FACSCanto II flow
cytometer (BD Biosciences).
Microarray analysis. Lung tissue was obtained from CS-treated
C57BL/6 mice (n  3) and FA-treated control animals (n  3) as
described above. Total RNA was isolated employing the RNeasy Mini
Kit (Qiagen) including digestion of remaining genomic DNA. The
Agilent 2100 Bioanalyzer was used to assess RNA quality, and only
high-quality RNA (RIN7) was used for microarray analysis; 300 ng
of total RNA were amplified using the Illumina TotalPrep RNA
Amplification kit (Ambion). Amplified cRNA was hybridized to
Mouse Ref-8 v2.0 Expression BeadChips (Illumina, San Diego, CA).
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Staining and scanning were done according to the Illumina expression
protocol. Data was processed by using the GenomeStudioV2010.1
software (gene expression module version 1.6.0) in combination with
the MouseRef-8_V2_0_R3_11278551_A.bgx annotation file. The
background subtraction option was used and an offset to remove
remaining negative expression values was introduced. CARMAweb
was used for quantile normalization (40). Statistical analyses were
performed by utilizing the statistical programming environment R [R
Development Core Team (39a)] implemented in CARMAweb. Gene-
wise testing for differential expression was done by employing the
limma t-test and Benjamini-Hochberg multiple testing correction
(false discovery rate  10%). Pathway enrichment analyses were
done with Ingenuity Pathway Software and significant terms (P 
0.05) were determined. Microarray data was submitted to GEO and
link for review was generated: http://www.ncbi.nlm.nih.gov/geo/
query/acc.cgi?tokenetknuseghzkfvkn&accGSE52509.
Statistics. Results are given as mean values  SD. One-way
ANOVA following Bonferroni posttest was used for all studies with
more than two groups. Analyses were conducted by use of GraphPad
Prism 6 software (GraphPad Software, La Jolla, CA).
RESULTS
B cells are required for iBALT formation after CS exposure.
In the lungs of severe COPD patients, increased T and B cell
numbers and LF-like structures have been described (21, 29).
To investigate the role of B cells in a CS-induced COPD mouse
model, B cell-deficient (MT) and WT mice were exposed to
CS for 1–6 mo. We found that in WT animals marginal
inflammatory cell infiltrates could be seen after 1 mo of CS
exposure compared with FA control mice. After 4 and 6 mo of
CS exposure, these infiltrates forming in WT mice, which we
termed iBALT, showed significant increases in volume as
shown by quantitative morphological assessment (Fig. 1, A and
B). Interestingly, the formation of iBALTs did not proceed in
the lungs of MT mice exposed to CS. Previously, Litsiou et al.
(29) have shown that CXCL13 plays an important role in LF
formation. Therefore, we investigated whether B cell deficiency in
vivo leads to altered CXCL13 expression. Using qPCR analysis
we found a significant induction of CXCL13 mRNA expression
in WT mice compared with MT mice, supporting the finding of
iBALT formation in WT mouse lungs only (Fig. 1C).
We further investigated the immune cell composition of
iBALT structures by staining for B and T lymphocytes. CS-
induced follicles in WT mice contained an abundance of
CD45R-positive B cells and CD3-positive T cells compared
with FA control and MT mice (Fig. 1, D and E). Neverthe-
less, we observed slightly increased numbers of CD3-positive
T cells in MT lungs after CS exposure.
These expected results demonstrate that in our clinically
relevant COPD mouse model B cells play crucial roles in
CS-induced formation of iBALT structures, which predomi-
nantly consist of B and T cells in WT mice.
B cell-deficient mice show different lymphocyte infiltration
in lung tissue after chronic CS exposure. Given the clear
differences in lung tissue inflammation and iBALT formation
in WT mice after CS exposure (Fig. 1), we aimed at confirming
our lung tissue results by using flow cytometric quantification
of B cells and CD4-positive T cell subsets in single-cell
suspensions of whole lungs from WT and MT mice. Com-
pared with FA animals, lungs from CS-exposed WT mice
revealed increased numbers of CD20-positive B cells starting
from 1 mo of exposure (Fig. 2A). Numbers of CD4-positive T
cell subtypes Th1 and Th2 increased during the whole time
course, but, except for lower Th1 cell numbers at 6 mo in
CS-exposed MT compared with WT mice, no significant
differences were observed for CS exposure and between WT
and MT mice, respectively (Fig. 2, C and D). Th17 cell
numbers were significantly different after 6 mo of CS exposure
in WT mice compared with CS-exposed MT and FA mice
(Fig. 2E). This was supported by significantly elevated IL-17
mRNA levels at the later time point of 6 mo (Fig. 2F).
Recently, T helper cell subsets have been further characterized
by dual expression of the prototypic cytokines. Therefore, we
undertook a more detailed analysis of the subsets found in our
CS-exposed mice. We did not observe an increase in IFN-
Th17, IL-17 Th2, and IFN-IL-17IL-4 cells after CS
exposure for 1 and 4 mo. After CS exposure for 6 mo, these
subsets were significantly increased in WT compared with FA-
and CS-exposed MT mice (IFN- Th17: 2.8  1.3% in WT
vs. 1.4  1.0% in MT mice; IL17 Th2: 0.6  0.2% in WT
vs. 0.2  0.1% in MT mice; IFN-IL-17IL-4: 0.5 
0.3% in WT vs. 0.1  0.1% in MT mice).
Because we did not observe increases in Th17 cells after CS
exposure of MT mice, we investigated whether B cell defi-
ciency alters the ability of CD4 T cells to differentiate into
Th17 cells in these animals. We found that there was no
differentiation defect in MT mice as indicated by comparable
Th17 levels after ex vivo stimulation of naive CD4 T cells from
WT and MT mice (12.5  2.0 vs. 14.1  3.0% Th17 cells).
These results demonstrate that chronic CS exposure is asso-
ciated with early increases in B cells and later increases of
Th17 cells in lung tissue of WT mice.
B cells play a critical role in CS-induced emphysema
development. CS-induced lung damage was assessed by lung
function analysis and by determining MLI with the computer-
assisted stereological toolbox. After 1 mo of chronic CS
exposure, significant changes in lung architecture and lung
compliance could be detected neither for WT nor for MT
mice compared with the respective FA control animals (Fig. 3).
However, there was a significant increase in emphysema de-
velopment after 4 mo of exposure to CS in the lungs of WT
mice compared with CS-exposed MT and FA mice. We
further exposed WT and MT animals to CS for another 2 mo
to enhance the CS-induced emphysema response. Interestingly,
there were no changes in MLI in MT animals even after 6 mo
of exposure to CS compared with FA control groups (Fig. 3, A
and B). Lung compliance was further augmented in WT com-
pared with MT mice exposed to CS for 4 and 6 mo (Fig. 3C).
In contrast, slight age-dependent increases in lung compliance
and MLI were observed for both WT and MT mice during the
whole time course. These data were confirmed by a reduction
of body weight in CS-exposed WT mice, whereas both MT
groups showed comparable body weight levels (Fig. 3D).
These results indicate that MT mice were protected against
CS-induced air space enlargement.
To rule out the possibility that MT mouse lungs are
generally protected against air space enlargement as shown by
Lucey et al. (30) for combined TNF-- and IL-1R-deficient
mice, as well as to clarify the role of immune cells, specifically
B cells in emphysema development, we treated MT mice
with PPE. In the elastase mouse model, emphysema develops
independent of immune cell (re)actions. Interestingly, oropha-
ryngeal administration of elastase resulted in severe pulmonary
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Fig. 1. Chronic cigarette smoke (CS) exposure leads to inflammatory cell recruitment and inducible bronchus-associated lymphoid tissue (iBALT) formation in
lungs of wild-type (WT) mice. Data were combined from 2 independent experiments (8 mice per group and per time point) and are given as mean values  SD;
1-way ANOVA following Bonferroni posttest with *P  0.05, **P  0.01, ***P  0.001. A: representative micrographs of hematoxylin and eosin (HE)-stained
lung tissue sections from filtered air (FA)- and CS-exposed WT mice vs. FA- and CS-exposed MT mice at indicated time points; scale bar 200 m. B: volume
of iBALT per basal membrane was determined via quantitative morphological assessment. C: mRNA expression of CXCL13 in lung tissue was measured by
qPCR and data are presented as relative expression to housekeeping control HPRT-1. D and E: immunohistochemistry for CD45R and CD3 in lung tissue from
FA- and CS-exposed WT mice (D) vs. FA- and CS-exposed MT mice (E) at indicated time points.
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Fig. 2. Staining for B cells and CD4 positive Th subsets in lung tissue after chronic CS exposure reveals increases in B cells and Th17 cells in WT mice. For flow
cytometric analysis single-cell suspensions were prepared from lung tissue. Surface marker stainings were directly performed with single-cell suspensions. For
intracellular cytokine stainings, mononuclear cells were isolated from total lung cells by density gradient purification, stimulated overnight and restimulated for 4 h prior
to fixation, permeabilization, and intracellular staining (see representative FACS plots for each staining performed). Data were combined from 2 independent experiments
(4–6 mice per group and per time point) and are given as mean values  SD; 1-way ANOVA following Bonferroni posttest with *P  0.05, **P  0.01, ***P 
0.001. A: mature B cells defined by expression of CD20 in FA- and CS-exposed WT mice. B: gating strategy for lung CD4 T cells expressing either IFN- (Th1),
IL-4 (Th2), or IL-17 (Th17) or different combinations thereof. FSC, forward scatter; SSC, side scatter. C–E: Th1 cells (C), Th2 cells (D), and Th17 cells (E) in FA-
and CS-exposed WT mice vs. FA- and CS-exposed MT mice. F: lung mRNA expression levels of target gene IL17A in comparison to housekeeping control HPRT-1
were determined via qPCR using cDNA synthesized from lung tissue homogenate.
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emphysema after 28 days in both WT and MT mice as
demonstrated by HE-stained lung tissue slides (Fig. 4A). Quan-
titative morphological assessment confirmed air space enlarge-
ment as indicated by significant increases in MLI for both
groups (Fig. 4B). The emphysematous changes in WT and
MT animals were associated with significantly increased lung
compliance (Fig. 4C). As expected, HE-stained lung sections
did not show any significant tissue inflammation in the lungs of
elastase-exposed WT and MT mice (Fig. 4A).
Our observations indicate that time-dependent iBALT for-
mation and expansion in WT mice after CS exposure are also
associated with the development of COPD.
Fig. 3. B cell deficiency protects against air space enlargement and lung dysfunction after chronic CS exposure. Data were combined from 2 independent
experiments (8 mice per group and per time point) and are given as mean values  SD; 1-way ANOVA following Bonferroni posttest with *P  0.05, **P 
0.01, ***P  0.001. A: representative micrographs of FA- and CS-exposed WT mice vs. FA- and CS-exposed MT mice at indicated time points; scale bar 200
m. B: quantitative measurement of emphysema was determined by design-based stereology of HE-stained lung tissue sections by use of an Olympus BX51 light
microscope equipped with the computer-assisted stereological toolbox newCAST. MLI, mean linear intercept. C: lung function measurements for dynamic
compliance (Cdyn) were performed in chronic CS-exposed WT and MT mice after 1, 4, and 6 mo. D: body weight (BW) changes are given in % compared
with respective FA controls.
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iBALT induces macrophage activation and polarization.
Since B cells and iBALT appear to be crucial for the devel-
opment of CS-induced emphysema, and macrophage-derived
MMP12 was described as being required for the induction of
experimental emphysema after prolonged CS exposure (18),
the role of B cells in accumulation and activation of tissue
macrophages in the chronic model was investigated. Despite
the lack of iBALT formation in MT mice after chronic CS
exposure (Fig. 1) we did not observe any differences in
secreted BAL cytokine and tissue mRNA expression levels for
TNF-, KC, and MCP1 in both CS-exposed groups (Fig. 5, A
and B). This was possibly due to similar CS-induced inflam-
matory reactions by lung epithelial cells. The comparable
levels of BAL cytokines and tissue mRNA expression were
confirmed by similar increases in total BAL inflammatory cell
counts in CS-exposed WT and MT mice. For both groups, a
significant and comparable increase in total cells counts in
CS-exposed mice compared with FA controls was observed at
all time points (fold increase compared with FA after 6-mo CS
exposure: 5.0  1.0 in WT vs. 4.2  1.3 in MT mice).
However, in the lung tissue of WT animals, we observed
significantly increased numbers of MMP12-stained macro-
phages located especially in iBALT as well as in the emphy-
sematous alveolar lumen (Fig. 6A). MT mice on the other
hand showed significantly lower staining for MMP12, which is
consistent with the data obtained for reduced iBALT formation
after CS exposure in these animals. Interestingly, we observed
staining for MMP12 in airway epithelial cells in MT mice.
Quantitative analysis of MMP12-expressing macrophage num-
bers in lung tissue also revealed significantly higher values for
CS-exposed WT compared with MT mice (Fig. 6B).
We further investigated mRNA expression levels for the
macrophage marker F4/80. We noticed increases in F4/80
mRNA expression after CS exposure for both WT and MT
mice, but levels were significantly higher in WT mice at 4 and
6 mo of exposure (Fig. 6C), indicating higher macrophage
accumulation in WT lung tissue. This was confirmed by qPCR
for MMP12, which showed strong CS-induced increases for
WT and MT mice, but also significantly higher expression for
WT animals at 4 and 6 mo of exposure (Fig. 6D). The stronger
increase in MMP12 expression in WT mice further led to a
higher MMP12-to-TIMP1 ratio in those animals, indicating a
disturbed balance of MMP12 and its inhibitor TIMP1 (Fig.
6E). Furthermore, Western blot analysis for MMP12 using
whole lung tissue lysates from WT and MT mice after 6 mo
of CS revealed a significant increase in active protein in
CS-exposed WT compared with MT mice (Fig. 6F). Because
MMP12 is considered a marker for M2 macrophage polariza-
tion, we also analyzed the gene expression profile of several
M1 and M2 markers. We did not observe increases in gene
expression for the M1 markers iNOS and IL-6 after CS
exposure in both WT and MT animals (Fig. 6G). In contrast,
besides MMP12, M2 markers FIZZ1 and Mrc1 were elevated
in WT mice starting from 4 mo of CS exposure. These data
strongly indicate that CS-induced iBALT is involved in mac-
rophage activation and positioning.
B cell-derived IL-10 activates macrophages. To decipher the
genes and pathways that might be involved in COPD devel-
opment in WT animals we examined the lung mRNA expres-
sion profile of 4- and 6-mo CS-exposed vs. FA-exposed mice
by microarray analysis using the Illumina Mouse Ref-8 v2.0
BeadChip. CS exposure induced a strong activation of two
Fig. 4. Elastase treatment results in severe
pulmonary emphysema after 28 days in both
WT and MT mice. Data were combined
from 2 independent experiments (8 mice per
group) and are given as mean values  SD;
1-way ANOVA following Bonferroni post-
test with *P  0.05, **P  0.01, ***P 
0.001. A: C57BL/6 mice were treated with
porcine pancreatic elastase to induce emphy-
sema. Representative micrographs of HE-
stained lung tissue slides reveal emphysema
development after 28 days; scale bar 200
m. B: quantitative morphological assess-
ment demonstrated air space enlargement as
indicated by significant increases in MLI for
both groups. C: lung function measurements
revealed significantly increased lung
compliance.
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pathways: “innate and adaptive immune cell communication”
and “IL-10 signaling,” among others (Table 1, Fig. 7A). We
selected two regulated genes involved in these pathways and
confirmed by an independent experiment the significant in-
creases in mRNA expression of TNF- (Fig. 5B) and IL1RN
(Fig. 7B).
Recently, it was shown that B cells are capable of polarizing
macrophages to an alternatively activated phenotype via secre-
tion of IL-10 (56). Therefore, we first investigated via qPCR
whether IL-10 was upregulated in our smoke model. Though
IL-10 mRNA expression levels were higher in CS-exposed
MT compared with WT mice at 1 mo, IL-10 mRNA expres-
sion increased significantly in WT animals at 6 mo of CS
exposure (Fig. 8A). Immunohistochemistry of WT lung tissue
for IL-10 demonstrated strong staining in areas of inflamma-
tory cell accumulation consisting predominantly of CD45R-
positive B cells but not in CD3-positive T cells (Fig. 8B).
Finally, in vitro stimulation of the murine B cell line A20 for
24 h with two concentrations of CS extract (CS 1 and 4%)
showed increases in IL-10 mRNA expression and secretion
after stimulation with both CS extract concentrations (Fig. 8, C
and D). In contrast, increased mRNA expression of inflamma-
tory genes such as IL-6, TNF-, and GM-CSF was only
observed in positive control (LPS)-treated cells (fold increase
compared with control: 2.5  0.2 for IL-6, 1.5  0.1 for
TNF-, 8.5  1.1 for GM-CSF).
To confirm the role for B cells in influencing macrophage
activation, we treated the macrophage cell line MH-S for 6
h with LPS and CS extract as well as with supernatants
obtained from A20 cells stimulated with LPS or CS extract
(1 and 4%) for 24 h. qPCR analysis of MMP12 showed a
strong increase in mRNA expression when MH-S cells
where stimulated with supernatants from CS extract-treated
A20 cells. Furthermore, to evaluate the possible role of B
cell-derived IL-10, we aimed at blocking IL-10 signaling in
MH-S cells treated with A20 supernatants by including an
anti-IL-10 antibody. This led to a significant reduction of
MMP12 expression in MH-S cells stimulated with superna-
tants from CS extract-treated A20 cells (Fig. 8E). These data
indicate that B cell-derived IL-10 is involved in macrophage
polarization and MMP12 upregulation after CS exposure in
vivo as well as in vitro.
DISCUSSION
Our study aimed at investigating the relationship between B
cell-dependent iBALT formation and the immunopathogenesis
of COPD. We identified what we believe to be a major
pathway that induces and maintains the severe inflammatory
response causing subsequent emphysema development in
COPD. The results presented here demonstrate that B cells are
involved in at least two mechanisms after CS exposure: firstly,
B cells are organized in iBALT, and secondly, they were found
to be potent regulators of macrophage accumulation and mac-
rophage-derived MMP12 production, thereby contributing to
emphysema development.
Fig. 5. Bronchoalveolar lavage (BAL) and
lung tissue inflammation is similar in WT
and MT mice after chronic CS exposure.
Data were combined from 2 independent
experiments (8 mice per group) and are
given as mean values  SD; 1-way ANOVA
following Bonferroni posttest with *P 
0.05, **P  0.01, ***P  0.001. A: lungs of
WT and MT mice were lavaged with 4 
0.5-ml aliquots of sterile PBS. BAL cytokine
secretion of TNF-, KC, and MCP1 was
determined by a magnetic bead-based mul-
tiplex assay. For this assay, BAL fluid was
concentrated (10) by ultrafiltration in cen-
trifugal filter devices. B: lung mRNA expres-
sion levels of target genes TNF-, KC, and
MCP1 compared with housekeeping control
HPRT-1 were determined via qPCR using
cDNA synthesized from lung tissue homog-
enate.
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There is considerable evidence that the CS-induced in-
flammatory response plays a major role in driving the
pathophysiological changes observed in COPD (5, 12).
Because of the high toxicity of both its gaseous and particle
phases (9, 47), CS persistently induces a neutrophil and
macrophage inflammatory response in the lower respiratory
tract of both humans and animals exposed in experimental
models (11, 24, 49). Whereas the acute reaction during the
Fig. 6. Macrophage markers are increased in the
lungs of CS-exposed WT mice. Data were com-
bined from 2 independent experiments (8 mice per
group and per time point) and are given as mean
values  SD; 1-way ANOVA following Bonferroni
posttest with *P  0.05, **P  0.01, ***P 
0.001. A: representative micrographs of immunohis-
tochemical stainings for MMP12 in lung sections
from FA controls and CS-exposed WT and MT
mice at indicated time points; scale bar 200 m. B:
quantitative analysis of MMP12-expressing macro-
phage numbers in lung tissue revealed significantly
higher values for CS-exposed WT compared with
MT mice. C–E: whole lung mRNA expression
levels of macrophage markers F4/80 (C) and
MMP12 (D) as well as the ratio of MMP12-to-
TIMP1 (E) were investigated compared with house-
keeping control HPRT-1 by qPCR. Relative tran-
script expression of target genes is given as 2	
CT
(
Ct  Cttarget 	 Ctreference), relative changes com-
pared with control are 2	

Ct values (

Ct 

Cttreated 	 
Ctcontrol). Mean values  SD; 1-way
ANOVA following Bonferroni posttest with *P 
0.05, **P  0.01, ***P  0.001. F: representative
Western blot and densitometric analysis for
MMP12 in lung tissue homogenate from WT and
MT mice after 6 mo of CS exposure. -Actin was
used as loading control. G: whole lung mRNA
expression levels of M1 macrophage markers iNOS
and IL-6 and M2 markers FIZZ1 and Mrc1 were
investigated compared with housekeeping control
HPRT-1 by qPCR.
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first week of CS exposure is dominated by a strong neutro-
philic and macrophage influx, the chronic phase starting
from 1 mo of CS exposure is additionally characterized by
infiltration of adaptive immune cells, i.e., lymphocytes, and
by progressive pathophysiological changes similar to those
observed in COPD patients, such as small airway remodel-
ing and septal tissue damage/emphysema (13, 46, 54). In our
present study, we found that B cell-deficient animals de-
velop emphysematous changes in an elastase mouse model
(Fig. 4); however, these animals were protected against
CS-induced emphysema development (Fig. 3). In contrast,
WT mice show functional and structural lung changes after
4 mo of CS exposure and this coincides with B cell accu-
mulation.
TLOs formed in the lung belong to iBALT, which is defined
as ectopic lymphoid tissue induced in response to infection or
inflammation. This allows local priming and clonal expansion
of B and T cells, antigen retention, somatic hypermutation,
affinity maturation, and immunoglobulin (Ig) class switching
(1, 28). By acquiring antigens from the airways, iBALT in-
duces a local inflammatory response and is responsible for the
maintenance of memory cells in the lungs (41). Therefore,
iBALT may be beneficial for the host by providing protection
against microbial colonization and infection of the lower re-
spiratory tract. Several studies have shown a protective role for
iBALT-related local immune responses in the context of influ-
enza infection (34, 43). However, the immune response medi-
ated by iBALTs might also be of a harmful nature in COPD
patients. Two recent studies investigated lymphoid neogenesis
in the COPD lung and confirmed the important role of
CXCL13 (6, 29). Litsiou et al. (29) found that CXCL13 levels
correlate with LF density in COPD patients and that CXCL13
promotes B cell migration to ectopic sites of lymphoid tissue
formation in the lung. Bracke et al. (6) performed prophylactic
and therapeutic treatment with an anti-CXCL13 antibody in
mice exposed to CS for 6 mo. This inhibited the formation of
pulmonary LFs and led to an attenuated BAL inflammation and
a partial protection against destruction of alveolar walls. We
were also able to confirm an upregulation of CXCL13 after CS
exposure in WT mice. Furthermore, the prevention of iBALT
formation in MT mice inhibited COPD development in our
study (Figs. 1 and 3).
This strongly points to an involvement of iBALT formation
in COPD pathogenesis, but the exact contribution to disease
development still remains unclear. Recent studies, mostly from
the field of autoimmune diseases such as multiple sclerosis (22,
55) and rheumatoid arthritis (51), have focused their attention
on the possible B cell roles that are independent of their
lymphoid neogenesis and antibody secreting function. Further
potent effector functions include antigen presentation, T cell
activation, and regulation as well as secretion of a variety of
immunmodulatory cytokines such as IL-6 and IL-10 (15, 23).
Interestingly, cytokine secretion by B cells has been shown to
influence and modulate differentiation and polarization of T
cells, macrophages, and dendritic cells during the development
of the immune response, thereby regulating immune reactions
(23). Moreover, macrophage effector functions can be directly
regulated by B cell-mediated cytokine secretion, which was
shown to be important for the outcome of various models of
infection, inflammation, and cancer. Kelly-Scumpia et al. (26)
demonstrated that B cell-dependent cytokine responses are
required for and enhance early innate immune responses during
bacterial sepsis. During viral infection with vesicular stomatitis
virus (VSV), B cells are indispensable for providing lympho-
toxin and thereby maintaining an antiviral macrophage pheno-
type that protects against fatal CNS invasion (32).
An important role has been attributed to B cell-derived IL-10
in various disease models. Increased production of anti-inflam-
matory IL-10 by B cells in multiple sclerosis, lupus, and
rheumatoid arthritis patients is capable of downregulating T
cell responses (19, 22). IL-10-producing B cells were also
shown to regulate macrophage function by decreasing their
phagocytic activity and cytokine and NO production (25, 39).
The modulated phagocytic activity of macrophages was de-
scribed as facilitating fungal infection in mice (38). Interest-
ingly, B1 cells, a B cell subset predominantly located in
peritoneal and pleural cavities, were described as the main
source of B cell-derived IL-10 (31), and IL-10 secreted by
Table 1. Enriched canonical pathways
Ingenuity Canonical Pathways 	log (P value) Ratio Molecules
Communication between innate and adaptive
immune cells
7.81E 00 1.34E	01 IL1A, CD83, Ccl9, IL33, CXCL10, TLR2, CCL4, IL1RN, FCER1G,
TLR7, CD86, CCL3L1/CCL3L3, Tlr13, CSF2, TNF
Role of hypercytokinemia/hyperchemokinemia
in the pathogenesis of influenza
5.04E 00 1.74E	01 IL33, CXCL10, IL1A, CCR5, CCL4, CCL2, IL1RN, TNF
IL-10 signaling 4.95E 00 1.54E	01 IL33, HMOX1, IL1A, CCR5, JUN, FCGR2A, IL1RN, NFKBIE,
IL10RB, CD14, FCGR2B, TNF
Atherosclerosis signaling 4.36E 00 1.08E	01 APOE, IL1A, MMP3, CMA1, MMP13, ALOX12, CCL11, PLA2G7,
IL33, ITGB2, PLA2G2D, CCL2, IL1RN, PLA2G4F, TNF
Dendritic cell maturation 3.34E 00 7.58E	02 PLCB2, IL1A, TYROBP, FCGR2A, NFKBIE, CD83, FCGR2B,
TREM2, IL33, TLR2, IL1RN, FCER1G, CD86, LY75, CSF2,
TNF
Cross talk between dendritic cells and natural
killer cells
2.65E 00 8.49E	02 CSF2RB, KLRD1, TYROBP, TLR7, CD86, CD83, TREM2, CSF2,
TNF
NF-B signaling 1.88E 00 7.18E	02 TLR2, IL33, TNIP1, IL1A, TGFBR1, CARD10, IL1RN, NFKBIE,
TGFBR3, FCER1G, TLR7, MALT1, TNF
Nicotine degradation II 1.86E 00 7.06E	02 UGT1A6, CYP4B1, FMO1, CSGALNACT1, UGT1A9, CYP1B1
Systemic lupus erythematosus signaling 1.32E 00 4.31E	02 IL33, IL1A, JUN, FCGR2A, IL1RN, TLR7, FCER1G, CD86, C6,
FCGR2B, TNF
Lung mRNA expression profiles of 4- and 6-mo cigarette smoke (CS)-exposed vs. filtered air-exposed mice were determined by microarray analysis using
Illumina Mouse Ref-8 v2.0 BeadChip. CS exposure induces a strong activation of 10 pathways as analyzed with Ingenuity Pathway software.
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these cells plays a role in polarizing macrophages to an
M2-like phenotype that promotes tumor growth in a mela-
noma model (56) and modulates wound-healing processes in
mice (35).
Macrophages are involved in the severe chronic lung
inflammation observed in COPD. In response to CS, mac-
rophages release cytokines and proteolytic enzymes and
generate oxidants, thereby causing tissue damage and per-
petuating inflammation and immune reactions (49). Because
MMP12 knockout mice are protected against CS-induced
macrophage recruitment and emphysema development,
these cells and their derived factors seem to be required for
disease onset and progression (18). Here, we showed strong
differences in lung tissue inflammation between WT and
MT mice, with significant increases in tissue macrophages
and upregulated MMP12 expression in CS-exposed WT
mice (Fig. 6). Moreover, we identified a role for B cell-
derived IL-10 in enhancing macrophage activation and
MMP12 upregulation (Fig. 8). To our knowledge, our data
are the first to provide a link between macrophages and B
cells involved in COPD pathogenesis.
Interestingly, CXCL13 neutralization was also shown to
directly affect macrophages (6). Bracke et al. (6) found
reduced expression of MMP12 in macrophages of CS-
exposed, anti-CXCL13-treated mice, which confirms our
findings of B cell-mediated MMP12 induction in macro-
phages. However, because CXCL13 treatment did not sig-
nificantly alter lung inflammation, alveolar enlargement,
and airway remodeling in their study, the authors concluded
that the innate immune system might be sufficient to induce
emphysema after CS exposure, as shown by D’hulst et al.
(12) using severe combined immunodeficiency (scid) mice,
which lack B and T lymphocytes (12). These animals
developed emphysema after CS exposure. But since scid
mice are from a BALB/c background, results are difficult to
compare with our study. Nevertheless, CS exposure of scid
and anti-CXCL13-treated mice also revealed a marked in-
crease in lung macrophages and MMP12 expression. On the
basis of these findings, we suggest that further investigation
and targeting of B cells or especially IL-10-releasing B cells
in the formation of iBALT and subsequent emphysema
development in a CS-induced COPD mouse model may shed
further light on mechanisms that could induce reparative
and regenerative processes in the COPD lung.
In conclusion, we have shown that CS exposure leads to B
cell-dependent iBALT formation, which contributes to the
pathogenesis of COPD via IL-10-induced macrophage activa-
tion and MMP12 upregulation. Unraveling the mechanisms
that are involved in and link innate and adaptive immune cell
responses to CS in COPD is of great clinical relevance. The
significant role for B cells and iBALT formation in CS-induced
emphysema development provides a new innovative mecha-
nism, which could be explored as a target for therapeutic
intervention in COPD patients. Targeting iBALT formation in
early stages after CS exposure to inhibit subsequent macro-
phage upregulation could be a promising option to prevent
COPD progression.
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Fig. 8. B cell-derived IL-10 secretion upregulates MMP12 expression. In vivo data from 2 independent experiments (8 mice per group and per time point) and
in vitro data from 3 independent experiments were combined and are given as mean values  SD; 1-way ANOVA following Bonferroni posttest with *P  0.05,
**P  0.01, ***P  0.001. A20-sup, supernatant from A20 cells; CS, cigarette smoke extract. A: IL-10 mRNA expression levels in lung tissue homogenates
were investigated compared with housekeeping control HPRT-1 by qPCR. B: representative micrographs of immunohistochemical stainings for IL-10 and CD3
and for IL-10 and CD45R in lung serial sections from CS-exposed WT mice after 6 mo of CS exposure; scale bar 200 m. C: at 24 h post-cigarette smoke extract
(CS) stimulation mRNA expression levels of IL-10 were significantly elevated in the B cell lymphoma line A20 as measured compared with housekeeping control
HPRT-1 by qPCR. D: IL-10 cytokine secretion in CS stimulated B cell lymphoma line A20 were investigated by ELISA of cell culture supernatants. E: MMP12
mRNA expression levels in the macrophage cell line MH-S with and without anti-IL-10 antibody treatment were investigated compared with housekeeping
control HPRT-1 by qPCR.
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